cms.bioaccessla.com

Tag: Chile

  • Does Chile’s post-trial access duty transfer to an M&A buyer?

    Yes. The second paragraph of Código Sanitario Article 111 C binds the sanitary-registration holder even when that party never held the provisional-use authorization and even when it acquired the registration afterwards. The free continued-supply duty travels with the Chilean registration by operation of law.

    I am Julio Martinez-Clark, CEO of bioaccess®. This page is the M&A diligence cut. For the full Art. 111 C analysis, device scope, and ISP role, use Post-trial access in Chile under Ley 20.850 and Código Sanitario Art. 111 C. For the 1 December 2026 DPA refresh under Ley 21.719, use Chile Ley 21.719 PTA DPA refresh.

    Short answer

    Article 111 C, first paragraph, gives the trial patient a right to free continuity of treatment after the study ends, for as long as therapeutic usefulness persists, from (1) the holder of the special provisional-use authorization and, later, (2) the holder of the sanitary registration. The second paragraph is the deal clause:

    “Esta obligación afectará al titular del registro sanitario, aun cuando no haya sido el titular de la autorización provisional o haya adquirido con posterioridad el registro sanitario.”

    Read that literally. An asset purchase that transfers only the Chilean registration — no trial contracts, no site agreements, no sponsor entity — still carries the tail. A licensing deal in which the licensee becomes the Chilean registration holder does the same. Standard reps and warranties rarely surface it, and standard product P&Ls never price it.

    Diligence questions before you buy or in-license

    1. Was any Chilean trial run under an ISP provisional-use authorization for this product, per the public research register ISP must keep under Article 111 A?
    2. How many participants remain on treatment, under what protocol definition of continued benefit?
    3. Who has supplied them since study close, under what import authorization?
    4. Do the indemnities in the purchase agreement acknowledge that the statutory duty to the patient sits with whoever holds the registration — not only with the seller’s representations?

    Breach of Title V is sanctioned under Article 111 G, which routes infractions to Book Ten of the Código Sanitario and to Ley 20.120. Book Ten’s general penalty article allows fines from one-tenth of a UTM up to 1,000 UTM, doubled on recidivism, plus suspension of distribution and use of the products concerned (Código Sanitario Art. 174).

    Devices and open-ended duration

    Devices are expressly in scope through Article 111 A’s “elementos de uso médico,” so the Art. 111 C duty is not a drug-only problem. Duration has no calendar end point: termination turns on loss of therapeutic usefulness under the study protocol, not commercial launch and not a fixed number of years. Brazil’s Lei 14.874/2024 Art. 33 VI permits interruption five years after commercial availability; Chile has a named obligor and no clock.

    Keep the Art. 111 C supply analysis separate from the data-protection contract. Ley 21.719 enters into force on 1 December 2026 and changes how Chilean PTA DPAs should be drafted — that is a companion workstream, not a substitute for the supply diligence above.

    bioaccess® operates regulatory, importadora and PTA architecture for Latin American post-trial programs. For Chile PTA diligence on a live asset or in-license, contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

    Related pillar

    Post-trial access in Chile under Ley 20.850 and Código Sanitario Art. 111 C

    Sources

    • Ley Núm. 20.850, Ministerio de Salud, promulgated 1 June 2015 — https://www.bcn.cl/leychile/navegar?idNorma=1078148
    • Código Sanitario (DFL 725), Article 111 C — https://www.bcn.cl/leychile/navegar?idNorma=5595
    • Chile PTA pillar: https://bioaccessla.com/blog/chile-post-trial-access-ley-20850
    • Chile Ley 21.719 DPA refresh: https://bioaccessla.com/blog/chile-ley-21719-pta-dpa-refresh

  • Which LATAM countries mandate post-trial access for medical devices?

    Four Latin American jurisdictions textually mandate post-trial access (PTA) for medical devices: Costa Rica (Ley 9234 Art. 53(k)), Brazil (Lei 14.874/2024 Art. 37), Chile (Código Sanitario Art. 111 A → 111 C), and Peru (DS 021-2017-SA Art. 2.1.36). Ecuador’s AM 00069-2024 does not. Argentina’s Disp. 12792/2016 is inferential.

    Most LATAM PTA statutes were drafted for medicines. Device sponsors who assume drug rules apply without reading product-class language understate exposure in four countries and overstate it in others.

    Short answer: which countries mandate device PTA?

    Express textual reach (4): Costa Rica, Brazil, Chile, Peru.

    Inferential / confirm-with-regulator: Argentina (productos y materiales; no dispositivo médico); Panama (Art. 68 “el producto” — confirm import pathway with DNFD).

    Medicines-only among binding PTA countries: Ecuador.

    Ten-country PTA mandate list: Argentina, Brazil, Panama, Chile, Peru, Ecuador, Costa Rica, Guatemala, Honduras, and Nicaragua (LATAM PTA operator map).

    Colombia disclaimer: Colombia does not currently mandate post-trial access by statute. When post-trial supply is required, bioaccess® can operate voluntary continuity programs on sponsor request. PTA statutory mandates in LATAM currently apply to Argentina, Brazil, Panama, Chile, Peru, Ecuador, Costa Rica, Guatemala, Honduras, and Nicaragua.

    Which jurisdictions expressly cover medical devices?

    Costa Rica — strongest express device language. Ley 9234 Art. 53(k) obliges free post-study provision of “el medicamento, dispositivo o procedimiento que ha sido objeto de investigación,” with enumerated exits. Art. 28 sets duration at “mientras lo requieran.” No other LATAM PTA instrument states device and procedure coverage this plainly (Map hub).

    Brazil — Chapter VI extends to devices and ATMPs. Lei 14.874/2024 Art. 37 applies the post-trial chapter to “produtos e dispositivos médicos” and experimental advanced therapies “no que couber.” Decreto 12.651/2025 Art. 31 speaks of produto sob investigação. Full analysis: Brazil PTA pillar.

    Chile — Art. 111 A pulls devices into Art. 111 C. Código Sanitario Art. 111 A requires the provisional-use authorization for “todo producto farmacéutico o dispositivo médico.” Art. 111 C then binds that authorization holder — and later the sanitary-registration holder — to free continuity “por todo el tiempo que persista su utilidad terapéutica” (Chile PTA pillar). ISP’s April 2026 device GCP guide (Res. Ex. N° 341 / 2.050) cites Art. 111 A but is silent on Art. 111 C; guidance silence does not erase the statute.

    Peru — definitional inclusion. DS 021-2017-SA Art. 2.1.36 defines producto en investigación as “un producto farmacéutico o dispositivo médico.” Título X (Arts. 115–118) operates on that term with no device carve-out (Peru PTA pillar).

    Which mandate countries are silent, inferential, or medicines-only?

    Ecuador — medicines-only. AM 00069-2024 Arts. 80–81 create a sponsor free-supply duty inside a medicines / natural-medicinal-products reglamento. Device exposure there runs through ethics-committee expectations and informed consent, not those articles (Map hub).

    Argentina — inferential. Disp. 12792/2016 Art. 3(f) covers products and “los materiales” that must match the approved study. Dispositivo médico does not appear. Confirm with ANMAT before assuming the cohort import route applies (Argentina PTA pillar).

    Panama — product language; confirm pathway. Decreto Ejecutivo 21/2026 Art. 68 refers to “el producto”; Chapter XIII covers medicines and other products for human health. Device studies fit a fair reading, but sponsors should confirm the import-permit-extension pathway with DNFD. Primary-source verification required for any device-class DNFD circular not already cited on the Panama pillar.

    Guatemala, Honduras, and Nicaragua sit in the ten-country PTA mandate set (Map hub); device-specific textual reach is thinner than the four express jurisdictions and should be verified before protocol lock. Guatemala AM 82-2019 vs AM 206-2021 supersession status remains primary-source verification required.

    What operational gaps remain after a device duty attaches?

    Obligation is not pathway. Costa Rica Art. 53(k) mandates free device provision, but Art. 55 addresses importation only before an approved study begins — no post-trial import route is identified in the statute (Map hub). Brazil Art. 37 is clear, yet RDC 38/2013 speaks of medicamento; build post-close import from the trial’s own authorizations (Brazil pillar).

    Chile’s open-ended “utilidad terapéutica” raises replacement, consumable, explant, and end-of-life questions the statute does not answer — close them in the protocol (Chile pillar). Peru’s duty can mean continued consumables or support for an implanted system with no device-specific carve-out (Peru pillar).

    Before first site activation: classify each country as express / inferential / medicines-only / no PTA statute; quote the device-scope article; name the post-close import mechanism or document that none exists; define device-system continuity in the protocol; appoint an importer of record after trial authorizations lapse.

    Working on a LATAM device PTA program? bioaccess® is a US-headquartered, LATAM-native operator for regulatory, importadora, and 2–8 °C GDP cold-chain functions. Contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

    Related pillar

    For the full 20-country mandate matrix, cost allocation, and duration comparative — including the ten binding-statute countries and Colombia’s no-PTA framing — read Post-trial access in Latin America: the operator’s map.

    Sources

    • Costa Rica — Ley N.º 9234 (Arts. 28, 53(k), 55): https://documentos.una.ac.cr/bitstream/handle/unadocs/5670/Texto%20Completo%20Norma%209234.pdf?sequence=1&isAllowed=y
    • Brazil — Lei nº 14.874/2024 Art. 37: https://www.planalto.gov.br/ccivil_03/_ato2023-2026/2024/lei/l14874.htm
    • Brazil — Decreto nº 12.651/2025 Art. 31: https://www2.camara.leg.br/legin/fed/decret/2025/decreto-12651-7-outubro-2025-798105-publicacaooriginal-176652-pe.html
    • Brazil — ANVISA RDC nº 38/2013: https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000038&seqAto=000&valorAno=2013&orgao=RDC/DC/ANVISA/MS&codTipo=&desItem=&desItemFim=&cod_menu=1696&cod_modulo=134&pesquisa=true
    • Chile — Código Sanitario Arts. 111 A, 111 C: https://www.bcn.cl/leychile/navegar?idNorma=5595
    • Chile — Ley 20.850: https://www.bcn.cl/leychile/navegar?idNorma=1078148
    • Chile — ISP Res. Ex. N° 341 / Res. Ex. 2.050: https://www.bcn.cl/leychile/navegar?idNorma=1223885
    • Peru — DS 021-2017-SA Arts. 2.1.36, 115–118: https://ensayosclinicos-repec.ins.gob.pe/images/Reglamento_de_EC.pdf
    • Ecuador — AM 00069-2024 Arts. 80–81, 95(c): https://www.espoch.edu.ec/wp-content/uploads/2025/10/ac-00069-2024_dic_31_compressed_1-1.pdf
    • Argentina — ANMAT Disposición 12792/2016 Art. 3(f): https://www.boletinoficial.gob.ar/detalleAviso/primera/154162/20161117
    • Colombia — Resolución 2378 de 2008: https://www.ins.gov.co/Normatividad/Resoluciones/RESOLUCION%202378%20DE%202008.pdf
    • LATAM PTA Operator Map: https://bioaccessla.com/blog/latam-post-trial-access-operator-map
    • Brazil PTA pillar: https://bioaccessla.com/blog/brazil-post-trial-access-lei-14874
    • Chile PTA pillar: https://bioaccessla.com/blog/chile-post-trial-access-ley-20850
    • Peru PTA pillar: https://bioaccessla.com/blog/peru-post-trial-access-ds-021-2017-sa
    • Argentina PTA pillar: https://bioaccessla.com/blog/argentina-post-trial-access-anmat-disposicion-12792
    • Panama PTA pillar: https://bioaccessla.com/blog/panama-post-trial-access-decreto-ejecutivo-21-2026

  • The legal architecture of Latin American post-trial access: SDEA, DPA, product liability, sponsor accession

    A Latin American post-trial access (PTA) program is a regulatory filing wrapped in four contracts. The filing is the visible part — an ANMAT import expediente, an ANVISA ofício, a DIGEMID authorization. The four contracts are what determine who answers to a regulator, who answers to a patient, and who answers to a plaintiff’s lawyer three years after the last shipment.

    Those four instruments are a Safety Data Exchange Agreement, a country-specific Data Processing Agreement, a product-liability allocation, and — the one most often missing — a sponsor accession mechanism that binds the marketing-authorization holder to the same schedules the operator signed. This piece sets out how we paper each of them and the five architectural mistakes that recur in draft PTA agreements we review.

    Why the paperwork carries more weight than the filing

    In nine Latin American jurisdictions the continued-supply duty is statutory and sits on the sponsor. Brazil’s Lei nº 14.874/2024 Art. 31 §4 states that “o fornecimento do medicamento será de responsabilidade do patrocinador,” and Art. 33 inciso VI releases the sponsor only five years after commercial availability in Brazil. Chile’s Código Sanitario Art. 111 C, inserted by Art. 34 of Ley 20.850, attaches the free-supply duty to the holder of the provisional-use authorization and then to the sanitary-registration holder — including a successor that acquired the registration later. Peru’s DS 021-2017-SA Art. 40(p) and Art. 89 put both the access duty and the funding on the sponsor. Panama’s Decreto Ejecutivo 21/2026 Art. 68 (Gaceta Oficial Digital 30510-C, 23 April 2026, which reglamentates Titles III and IV of Ley 84 de 14 de mayo de 2019) names investigadores y patrocinadores as co-obligors.

    None of those statutes names an operator, an importadora, or a managed-access vendor. The obligation is the sponsor’s by law. Everything the operator does — the import authorization under Disposición ANMAT 12792/2016 Art. 4, the cold-chain leg, the pharmacovigilance intake — is performed on behalf of an obligor that remains the obligor. If the contract does not say so with precision, the operator has effectively assumed a statutory duty it has no legal standing to discharge.

    Pillar 1: the Safety Data Exchange Agreement

    The SDEA is the instrument that connects local adverse-event intake to the sponsor’s global pharmacovigilance system. It should be executed within 30 days of the Work Order, not left to a later “PV annex to follow.”

    Three ICH guidelines set the substance. ICH E2A fixes the expedited-reporting clock: fatal or life-threatening unexpected adverse drug reactions require notification “as soon as possible but no later than 7 calendar days after first knowledge by the sponsor,” followed by a fuller report “within 8 additional calendar days” (§III.B.1), while all other serious unexpected ADRs run on a 15-calendar-day clock (§III.B.2). Because the clock starts on sponsor knowledge, the SDEA must set an internal onward-transmission deadline for the local operator that is materially shorter — otherwise the sponsor’s regulatory clock is being consumed by the operator’s intake queue. ICH E2F governs periodic reporting: the DSUR is an annual report with a data lock point on “the last day of the one-year reporting period” and submission “no later than 60 calendar days after the DSUR data lock point” (§2.2), so the SDEA must specify who supplies PTA-cohort line listings into that cycle and by when. ICH E3 §12 sets the safety-evaluation structure the underlying trial report already follows, which is the format PTA safety data should feed into rather than a parallel one.

    Practical drafting points: name the sponsor’s global PV mailbox and the operator’s PV contact by role, define the reconciliation cadence, and state expressly that regulatory reporting to the local authority is the sponsor’s obligation performed through the operator as agent, with the operator’s duty limited to timely, accurate onward transmission.

    Pillar 2: the Data Processing Agreement — country by country

    There is no single Latin American data-protection instrument, so there is no single DPA. The controlling article set changes by jurisdiction:

    Jurisdiction Instrument Transfer article Notes for PTA drafting
    Argentina Ley 25.326 Art. 12(1)–(2) Transfer to countries without adequate protection is prohibited; Art. 12(2)(b) carves out medical-data exchange where the affected person’s treatment requires it. Art. 11(4) makes the transferee subject to the transferor’s obligations and imposes joint liability.
    Argentina (clauses) AAIP Resolución 198/2023 Anexo I Approves two model clause sets: responsable–responsable and responsable–encargado. Use the latter where the operator processes only on sponsor instruction (Cláusula 6.1).
    Brazil Lei nº 13.709/2018 (LGPD) Arts. 33–36 Art. 33 II(a)–(b) permits transfer on specific or standard contractual clauses; Art. 33 VIII permits it on specific, highlighted consent distinguished from other purposes.
    Mexico LFPDPPP (DOF 20 March 2025) Arts. 35–36 Health data is sensitive (Art. 2 fr. VI) and requires express written consent (Art. 8). Art. 36 fr. II exempts transfers necessary for medical treatment or health-service management.
    Chile Ley 19.628 → Ley 21.719 Art. 10 → Arts. 27–29 Ley 21.719 was published 13 December 2024 and enters into force 1 December 2026. Any Chilean PTA DPA signed now should be drafted to the Arts. 27–29 transfer regime, not only to Ley 19.628 Art. 10.
    Peru DS 016-2024-JUS (Reglamento, Ley 29733) Arts. 18–20 In force 120 calendar days after publication (31 March 2025). Art. 20.1 permits model contractual clauses imposing “cuando menos las mismas obligaciones” on the importer.
    Colombia Ley Estatutaria 1581 de 2012 Art. 26 Health data is sensitive (Art. 5); Art. 26(b) carves out medical-data exchange required by the data subject’s treatment. Otherwise the SIC issues a declaración de conformidad (Art. 26, par. 1).

    The operator-side drafting position is the same everywhere: the sponsor is responsable/controller, the operator is encargado/operator, processing is limited to documented instructions, sub-processing requires prior written consent, and the operator returns or deletes on termination subject to statutory retention. Where the destination country has no adequacy finding, attach the applicable model clauses as a schedule rather than describing them in the body.

    The Argentina adequacy mistake

    The most common error in Argentine PTA drafting is treating Commission Decision 2003/490/EC as if it authorised outbound transfers from Argentina. Article 1 reads: “Argentina is regarded as providing an adequate level of protection for personal data transferred from the Community.” Article 2 confines the decision to adequacy in Argentina “with a view to meeting the requirements of Article 25(1) of Directive 95/46/EC.” The instrument is unidirectional — EU to Argentina.

    A PTA data flow from Argentine sites to a sponsor in the United States, or to an access vendor in the Netherlands, is an Argentine outbound transfer governed by Ley 25.326 Art. 12, and the correct instrument is the AAIP responsable–encargado model agreement under Resolución 198/2023, not a citation to the 2003 decision. Treating the adequacy finding as reciprocal is a defect that survives review because it looks like a considered legal position.

    Pillar 3: product liability sits with the sponsor

    The operator is not the manufacturer, does not hold the marketing authorization, and cannot practically bear product-liability risk for the product itself. A managed-access or expanded-access vendor is in the same position. Neither controls design, manufacture, batch release, labelling content, or the safety profile — so neither can defend a product claim on the merits or insure it economically.

    Our drafting position, and the position we recommend to any operator in this role:

    • The sponsor or titular defends and indemnifies the operator against third-party claims arising from the product itself, including design, manufacture, and labelling defects.
    • The sponsor maintains product-liability insurance covering the PTA territories for the duration of the program plus a tail, and provides certificates on request.
    • The operator’s liability cap covers operator services only. Product liability sits outside the cap.
    • Carve-outs outside the cap in both directions: gross negligence, wilful misconduct, breach of confidentiality, intellectual-property infringement, and breach of data-protection obligations.

    The cap itself is negotiable, usually expressed against fees paid under the Work Order over a defined lookback. Its composition is not: a cap that silently absorbs product liability converts a services agreement into an uninsured product warranty.

    Pillar 4: sponsor accession as a condition precedent

    Because the sponsor holds the statutory supply duty, the product liability, the marketing authorization, and the primary pharmacovigilance obligation, an operator’s Work Order should be conditioned on sponsor accession. Two mechanisms work:

    1. Direct accession — the sponsor executes a short accession instrument to the schedules that allocate safety data exchange, data processing, and liability (in our template set, schedules C, E and F).
    2. Tripartite side letter — the sponsor, the access vendor or intermediary, and the operator sign a single side letter confirming the sponsor’s indemnity, insurance, PV ownership, and patient-continuity funding, with the underlying Work Order otherwise unchanged.

    Either way the Work Order should not become effective until accession is signed. Without it, the operator holds a services contract with a counterparty that cannot deliver the indemnity the contract assumes, and the patient-continuity commitment has no funded obligor behind it.

    Five architectural mistakes we see repeatedly

    1. No sponsor accession condition. The operator signs with an intermediary and inherits an unfunded, uninsurable duty.
    2. Product liability inside the operator’s cap. Structurally wrong for a non-manufacturer.
    3. The reciprocal-adequacy error. Argentina→US or Argentina→NL flows papered as if Decision 2003/490/EC covered them.
    4. No patient-continuity run-off. Termination should trigger a defined run-off — our default is 90 days — during which supply, PV intake, and cold-chain continue at the sponsor’s cost.
    5. No sponsor-funded continuity trigger. If the sponsor terminates the program or the access vendor disengages, the continuity obligation must be expressly sponsor-funded, or patients absorb the commercial dispute.

    Governing law, dispute resolution, and pre-send gates

    For cross-border PTA services agreements with a US-headquartered operator, Delaware law with AAA-ICDR arbitration seated in New York is a sensible default: neutral to the LATAM performance jurisdictions, familiar to sponsor counsel, and enforceable across the region under the New York Convention. Local-law carve-outs remain necessary for the statutory duties themselves, which are not contractible away.

    Before any PTA agreement leaves our desk it passes four gates: (1) a counsel memo verifying the regulatory framework and article citations for each performance jurisdiction; (2) named performing entities, including the habilitada local entity and the importadora of record; (3) sponsor accession path agreed in principle, in writing, before signature; and (4) harmonized statutory-obligation language, so that the same duty is not described one way in the recitals and another way in the schedules.

    Frequently asked questions

    What legal architecture does a LATAM post-trial access program require?
    Four instruments beyond the services agreement itself: a Safety Data Exchange Agreement connecting local adverse-event intake to the sponsor’s global pharmacovigilance system; a country-specific Data Processing Agreement built on the applicable transfer article (Argentina Ley 25.326 Art. 12, Brazil LGPD Arts. 33–36, Colombia Ley 1581 Art. 26, and so on); a product-liability allocation placing defence, indemnity, and insurance on the sponsor or titular; and a sponsor accession mechanism binding the marketing-authorization holder to those schedules. The regulatory filing — import authorization, ethics submission — is separate and downstream.

    What is a Safety Data Exchange Agreement (SDEA) in PTA?
    An SDEA is the bilateral agreement that defines how safety information moves from the PTA site and local operator into the sponsor’s global pharmacovigilance system. It should be executed within 30 days of the Work Order and built on ICH principles: ICH E2A §III.B for the 7-day and 15-calendar-day expedited-reporting clocks, ICH E2F §2.2 for annual DSUR periodicity and the 60-day post-data-lock-point submission window, and ICH E3 §12 for the safety-evaluation structure the data must fit. It names PV contacts, sets onward-transmission deadlines shorter than the sponsor’s regulatory clock, and fixes a reconciliation cadence.

    What is a Data Processing Agreement (DPA) in Argentine PTA?
    It is the instrument that makes an Argentine PTA data flow lawful under Ley 25.326. Art. 12(1) prohibits transfer to countries or organisations that do not provide adequate protection levels, and Art. 11(4) makes the transferee subject to the transferor’s obligations with joint liability. Where the sponsor sits in a country without an Argentine adequacy finding, the practical route is the responsable–encargado model agreement approved by AAIP Resolución 198/2023, attached as a schedule. Cláusula 6.1 limits the importer to the exporter’s documented instructions, with no decision-making power over scope or content.

    Does EU Commission Decision 2003/490/EC cover Argentina→US or Argentina→EU data flows?
    No. Article 1 of Decision 2003/490/EC regards Argentina as adequate for “personal data transferred from the Community,” and Article 2 limits the decision to adequacy in Argentina for the purposes of Article 25(1) of Directive 95/46/EC. The decision is unidirectional: EU to Argentina. An outbound transfer from Argentine sites to a US sponsor or a Dutch access vendor is governed by Ley 25.326 Art. 12 and requires its own adequacy basis, statutory exception, or model clauses. Article 3 of the decision, in fact, gives EU authorities power to suspend flows to recipients in Argentina — the opposite of a reciprocal permission.

    Who bears product liability in a PTA program — the sponsor, the manufacturer, or the operator?
    The sponsor or the titular of the marketing authorization. The operator is not the manufacturer, does not hold the authorization, and does not control design, manufacture, batch release, or labelling — so it cannot defend a product claim on the merits or insure it at a rational price. The correct architecture has the sponsor defend and indemnify the operator for product-related third-party claims, maintain product-liability insurance covering the PTA territories for the program term plus a tail, and accept that product liability sits outside the operator’s services liability cap.

    Why should PTA operators condition the Work Order on sponsor accession?
    Because the sponsor holds every obligation the Work Order depends on: the statutory continued-supply duty, the marketing authorization, primary pharmacovigilance responsibility, product liability, and the funding for patient continuity. An operator that contracts only with an intermediary holds an indemnity from a party that does not control the product and a continuity commitment with no funded obligor. Making accession a condition precedent — rather than a post-signature action item — is the only reliable way to ensure the risk allocation in the schedules is enforceable against the party that can actually perform it.

    What is a tripartite side letter in LATAM PTA?
    A single short instrument signed by the sponsor, the access vendor or intermediary, and the local operator, used where the sponsor will not accede directly to the operator’s schedules. It confirms four things: the sponsor’s defence and indemnity for product-related claims; the sponsor’s product-liability insurance covering the PTA territories; sponsor ownership of primary pharmacovigilance and regulatory reporting; and sponsor funding of patient continuity, including any run-off period. It leaves the underlying Work Order commercial terms untouched, which is usually why it is the faster path to signature.

    What is the standard liability cap in a LATAM PTA Work Order?
    There is no single market standard, and any figure quoted as one should be treated with suspicion. Caps are typically expressed as a ceiling tied to fees paid under the Work Order over a defined lookback period. The more consequential negotiation is not the number but the composition — what the cap covers and what sits outside it. A cap that quietly includes product liability turns a services agreement into an uninsured product warranty, which is a worse outcome for the operator than a low number with clean carve-outs.

    What carve-outs should sit outside the liability cap?
    Five, in both directions: gross negligence, wilful misconduct, breach of confidentiality, intellectual-property infringement, and breach of data-protection obligations. Product liability should also sit outside the operator’s cap, because the operator is not the manufacturer. Data-protection breach deserves particular attention in Latin America: Argentina’s Ley 25.326 Art. 11(4) imposes joint liability between transferor and transferee, and Mexico’s LFPDPPP Art. 59 fr. IV allows sanctions for sensitive-data infractions to be increased up to twofold, so capped data-protection exposure can be materially lower than actual statutory exposure.

    What is the standard patient-continuity run-off period?
    Our default drafting position is 90 days from the effective date of termination. During that window, product supply, pharmacovigilance intake, and cold-chain and importation services continue at the sponsor’s cost while the sponsor arranges an alternative route — a successor operator, an extension study, or transition into commercial or public-system supply. The reason to fix a defined period rather than “a reasonable transition” is that the statutory obligations do not pause: Brazil’s Lei 14.874/2024 Art. 33 lists exhaustive interruption grounds, and contract termination between a sponsor and its operator is not one of them.

    Should managed-access-program specialists require sponsor accession too?
    Yes, and for the same structural reason. A managed-access or expanded-access specialist occupies the same position as a regional operator: it is not the manufacturer, does not hold the marketing authorization, and cannot bear product-liability risk for the product. Whether the intermediary is a global access platform, a specialty distributor, or a regional CRO, the party with the statutory supply duty and the insurable product risk is the sponsor. Any access architecture that leaves the sponsor outside the contractual chain has a gap at exactly the point where a patient-harm claim would land.

    Working on a LATAM post-trial access program? bioaccess® is a US-headquartered, LATAM-native operator running regulatory, importadora, and 2–8 °C GDP cold-chain functions directly across the region. If you’re evaluating PTA feasibility in Argentina, Brazil, Chile, Peru, Panama, Mexico or Colombia, contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

    Sources

    • ICH E2A, Clinical Safety Data Management: Definitions and Standards for Expedited Reporting — https://database.ich.org/sites/default/files/E2A_Guideline.pdf
    • ICH E2F, Development Safety Update Report — https://database.ich.org/sites/default/files/E2F_Guideline.pdf
    • ICH E3, Structure and Content of Clinical Study Reports — https://database.ich.org/sites/default/files/E3_Guideline.pdf
    • Commission Decision 2003/490/EC of 30 June 2003 (Argentina adequacy) — https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32003D0490
    • Argentina, Ley 25.326 (Protección de los Datos Personales) — https://servicios.infoleg.gob.ar/infolegInternet/anexos/60000-64999/64790/texact.htm
    • Argentina, AAIP Resolución 198/2023 (RESOL-2023-198-APN-AAIP, BO 18/10/2023), model international-transfer clauses — https://servicios.infoleg.gob.ar/infolegInternet/anexos/390000-394999/391538/norma.htm
    • Argentina, AAIP Resolución 198/2023 Anexo I (IF-2023-108581614-APN-DNPDP#AAIP) — https://servicios.infoleg.gob.ar/infolegInternet/anexos/390000-394999/391538/res198.pdf
    • Argentina, Disposición ANMAT 12792/2016 (post-study import procedure) — https://www.boletinoficial.gob.ar/detalleAviso/primera/154162/20161117
    • Argentina, Disposición ANMAT 7516/2025 (GCP, in force 1 December 2025) — https://www.boletinoficial.gob.ar/detalleAviso/primera/332695/20251009
    • Brazil, Lei nº 13.709/2018 (LGPD) — https://www.planalto.gov.br/ccivil_03/_ato2015-2018/2018/lei/l13709.htm
    • Brazil, Lei nº 14.874/2024, Arts. 30–37 — https://www.planalto.gov.br/ccivil_03/_ato2023-2026/2024/lei/l14874.htm
    • Brazil, Decreto nº 12.651/2025, Art. 31 — https://www2.camara.leg.br/legin/fed/decret/2025/decreto-12651-7-outubro-2025-798105-publicacaooriginal-176652-pe.html
    • Mexico, Ley Federal de Protección de Datos Personales en Posesión de los Particulares (DOF 20 March 2025; last reform DOF 14 November 2025) — https://www.diputados.gob.mx/LeyesBiblio/pdf/LFPDPPP.pdf
    • Chile, Ley 19.628 sobre Protección de la Vida Privada — https://www.bcn.cl/leychile/navegar?idNorma=141599
    • Chile, Ley 21.719 (published 13 December 2024; in force 1 December 2026) — https://www.bcn.cl/leychile/navegar?idNorma=1209272
    • Chile, Ley 20.850 and Código Sanitario Art. 111 C — https://www.bcn.cl/leychile/navegar?idNorma=1078148
    • Peru, Decreto Supremo N° 016-2024-JUS (Reglamento de la Ley 29733) — https://www.gob.pe/institucion/anpd/normas-legales/6554453-16-2024-jus
    • Peru, Reglamento de Ensayos Clínicos, DS 021-2017-SA, Arts. 115–118 — https://ensayosclinicos-repec.ins.gob.pe/images/Reglamento_de_EC.pdf
    • Colombia, Ley Estatutaria 1581 de 2012 — https://www.funcionpublica.gov.co/eva/gestornormativo/norma.php?i=49981
    • Panama, Decreto Ejecutivo No. 21 de 23 de abril de 2026, Art. 68, Gaceta Oficial Digital No. 30510-C (primary-source Gaceta PDF, read 6 September 2026)

  • Post-trial access in Chile under Ley 20.850 and Código Sanitario Art. 111 C

    Chile obliges the holder of a clinical trial’s provisional-use authorization — and, later, whoever holds the product’s sanitary registration — to keep supplying the trial treatment free of charge for as long as it retains therapeutic usefulness. The rule is Article 111 C of the Código Sanitario, inserted by Ley 20.850, and it is written in a way that binds an acquirer who was never involved in the trial.

    That last clause is why Chile belongs on a deal checklist rather than only on a clinical operations checklist. A US sponsor can sell or out-license a Chilean-registered product and hand the buyer an open-ended, free-of-charge supply duty that appears nowhere in the trial budget, the product P&L, or most representations and warranties.

    What Ley 20.850 actually did

    Ley Núm. 20.850, “Crea un sistema de protección financiera para diagnósticos y tratamientos de alto costo y rinde homenaje póstumo a don Luis Ricarte Soto Gallegos,” was promulgated on 1 June 2015 by the Ministerio de Salud (BCN Ley Chile) and published in the Diario Oficial on 6 June 2015, a date recited in later ministerial decrees (Decreto 11 Exento, 30 April 2025).

    The statute is best known for the high-cost treatment fund it created. But Article 34 of the same law added two new Titles to Book Four of the Código Sanitario: Title V on clinical trials of pharmaceutical products and elements of medical use (Arts. 111 A to 111 G), and Title VI on defective health-product liability (Arts. 111 H to 111 N). Chile’s trial authorization regime, its post-trial access duty, its strict-liability rule for trial injury and its ten-year limitation period all arrived in one act (Código Sanitario, DFL 725). Ley 20.850 restates the same right in Article 17: trial patients “tendrán derecho… a la continuidad gratuita de los tratamientos recibidos conforme al protocolo de estudio, aun cuando éste haya finalizado y mientras subsista su utilidad terapéutica” (Ley 20.850, Art. 17).

    What Article 111 C requires

    The operative text is short. Article 111 C, first paragraph:

    “El paciente sujeto de ensayo clínico tendrá derecho a que, una vez terminado éste, el titular de la autorización especial para uso provisional con fines de investigación y, con posterioridad en su caso, el titular del registro sanitario del producto sanitario de que se trate, le otorgue sin costo para el paciente la continuidad del tratamiento por todo el tiempo que persista su utilidad terapéutica, conforme al protocolo de investigación respectivo.” (Código Sanitario Art. 111 C)

    Four things follow. It is a patient right, not a sponsor best-effort. It is free to the patient, with no cost-sharing carve-out. It has no calendar end point: termination turns on loss of therapeutic usefulness, not commercial launch, not reimbursement listing, not a fixed number of years. And it is anchored to the study protocol, so the protocol’s definition of continued benefit stays load-bearing years after database lock. Brazil caps the equivalent duty at five years from commercial availability; Chile has a named obligor and no clock.

    Breach is sanctioned under Article 111 G, which routes Title V infractions to Book Ten of the Código Sanitario and to Ley 20.120. Book Ten’s general penalty article allows fines from one-tenth of a UTM up to 1,000 UTM, doubled on recidivism, plus suspension of distribution and use of the products concerned (Código Sanitario, Art. 174).

    Devices are expressly in scope

    Most Latin American post-trial provisions are drafted around medicines and leave device sponsors to argue about scope. Chile does not. Article 111 A states that the special provisional-use authorization “se requerirá para todo producto farmacéutico o dispositivo médico,” and Title V is titled for “productos farmacéuticos y elementos de uso médico” (Código Sanitario Art. 111 A). Because Article 111 C attaches to the holder of that same authorization, the post-trial duty reaches device sponsors on the face of the text. The Ministerio de Salud may exempt, by supreme decree, device categories whose use “no conlleve un riesgo relevante para las personas” — that is an exemption from the authorization requirement, and a sponsor relying on it should confirm the specific decree rather than assume one exists for its class.

    For an implantable or capital-equipment device, continuity “for as long as therapeutic usefulness persists” raises questions the statute does not answer: replacement units, consumables, explant and revision, software maintenance, end of product life. Those gaps close in the protocol and the informed consent, because Article 111 C points back to the protocol for its content.

    The obligation follows the registration, not the sponsor

    The second paragraph of Article 111 C is the one that changes deal economics:

    “Esta obligación afectará al titular del registro sanitario, aun cuando no haya sido el titular de la autorización provisional o haya adquirido con posterioridad el registro sanitario.” (Código Sanitario Art. 111 C)

    Read that literally. The duty binds the sanitary-registration holder even where that party never held the provisional-use authorization, and even where it acquired the registration afterwards. It travels with the asset by operation of law. An asset purchase that transfers only the Chilean registration — no trial contracts, no site agreements, no sponsor entity — still carries the tail. A licensing deal in which the licensee becomes the Chilean registration holder does the same.

    Four diligence questions follow for anyone buying a product with Chilean clinical history. Was any Chilean trial run under an ISP provisional-use authorization for this product, per the public research register the ISP must keep under Article 111 A? How many participants remain on treatment, under what protocol definition of continued benefit? Who has supplied them since study close, under what import authorization? And is there seller indemnity for a duty Chilean law places on the registration holder directly — noting that allocation between the parties does not extinguish the duty toward the patient.

    The exposure is unbounded in duration by design, which makes it hard to reserve for and easy to miss. We identified no published Chilean enforcement decision quantifying the tail, so today’s practical risk is less about fines than about inheriting an undisclosed supply commitment and finding it after closing.

    Where the ISP fits

    The Instituto de Salud Pública is the regulator on both ends of this obligation. It grants the provisional-use authorization under Article 111 A — valid for no more than one year, renewable for equal successive periods — accredits research centers under Article 111 D, and fiscalizes protocols, informed consents, good clinical practice and adverse-event reporting (Código Sanitario Arts. 111 A and 111 D). Article 111 D also makes any confidentiality obligation in a protocol or agreement unenforceable against the ISP. The authorization is a paid service: prestación 4111035 is listed at CLP $1,129,893 plus IVA (ISP). Article 99 separately lets the ISP provisionally authorize unregistered pharmaceutical products for trials and for urgent medicinal uses arising from shortage or inaccessibility (Código Sanitario Art. 99; ISP guidance).

    What the ISP has not published is Article 111 C guidance. Its “Guía de consideraciones generales para estudios clínicos” (Res. Ex. N° 173, 29 January 2024 — BCN) and its first-edition “Guía de investigación clínica de dispositivos médicos en humanos. Buenas prácticas clínicas” (Res. Ex. N° 341, 7 April 2026, recorded as Res. Ex. 2.050 — BCN; ISP) were both reviewed for post-trial content. The device guide cites Article 111 A and covers post-participation care for adverse events and post-market clinical follow-up, but not Article 111 C or continued supply. Chile’s newest device GCP guidance is silent on the obligation its own statute imposes on device sponsors.

    CENABAST and the exceptional-import backstop

    CENABAST is Chile’s public procurement and supply agency, and Ley 20.850 gave it powers that matter when a supply chain breaks. Under Article 15, where a product covered by the high-cost system has its registration suspended, cancelled or lapsed, CENABAST may — with prior Ministry of Health authorization, and only where no alternative exists at the maximum industrial price — exceptionally import and distribute it “independientemente si cuentan o no con autorización o registro sanitarios.” The same article deems those circumstances public-health grounds under Chile’s industrial property law and closes with a liability rule: “Los titulares de los registros o autorizaciones sanitarias, los productores o los importadores serán responsables civilmente por la falta de continuidad de los tratamientos” (Ley 20.850, Art. 15). Article 31 adds the procurement side: contracting one product with more than one supplier where continuity requires it, direct contracting where CENABAST holds the registration itself, and requesting a provisional sanitary registration in shortage situations (Ley 20.850, Art. 31; CENABAST).

    This is a state backstop for continuity of covered treatments, with civil liability pointed back at the registration holder. It is not a route to hand off an Article 111 C duty.

    The Ricarte Soto Fund as the exit ramp, and its limits

    Ley 20.850’s financial protection system is insured by FONASA for beneficiaries of every Chilean health system — FONASA, isapres, CAPREDENA and DIPRECA — regardless of socioeconomic status, and covers 100% of the cost of the medicines, medical devices or foods expressly guaranteed for each defined health problem (Superintendencia de Salud). ChileAtiende describes it as guaranteeing diagnosis and treatment for 27 high-cost conditions (ChileAtiende). Inclusion runs through a supreme decree under Article 5, subject to a cost threshold, favourable scientific evaluation, recommendation and an incorporation decision (Ley 20.850, Art. 5).

    Getting a product into that decree is the cleanest way for Article 111 C exposure to become a state-funded treatment rather than a private supply obligation. It is also slow, competitive and outside the sponsor’s control — and nothing in Article 111 C ends the duty on listing. Treat it as practical mitigation, not a legal termination event.

    What the statute leaves open

    First, Title V repeatedly refers to a reglamento — adverse-event reporting under Article 111 B, center accreditation under Article 111 D, insurance under Article 111 F. We identified no ISP or MINSAL instrument in this review that operationalizes Article 111 C specifically. The obligation is statutory and self-executing on its face; the mechanics are not written down.

    Second, entry into force. The first transitory article provides that “las normas de esta ley regirán a contar de la entrada en vigencia del decreto a que se refiere el artículo 5º” (Ley 20.850, disposiciones transitorias). The Article 34 amendments sit in the consolidated Código Sanitario text and the ISP has operated the Article 111 A authorization since, but how that clause interacts with the Title V insertions is a question for Chilean counsel, not for a CRO.

    Third, “utilidad terapéutica” is undefined. Chile’s medical academy, writing on Title V and its draft reglamento in Revista Médica de Chile, argued that continuation should be decided case by case once final results including safety are known, by the patient and treating physician, and that “se necesita una definición de utilidad más objetiva y fácil de determinar” (Rev Med Chile). Until that definition exists, the protocol is the only instrument that sets the endpoint — an argument for drafting it at protocol design, not at study close.

    Working on a LATAM post-trial access program? bioaccess® is a US-headquartered, LATAM-native operator running regulatory, importadora, and 2–8 °C GDP cold-chain functions directly across the region. If you’re evaluating PTA feasibility or acquisition exposure in Chile, contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

    Frequently Asked Questions

    Does Chile require post-trial access?
    Yes. Article 111 C of the Código Sanitario gives clinical trial participants a right to continued treatment after the trial ends, free of charge, for as long as the treatment retains therapeutic usefulness. The duty falls first on the holder of the ISP special provisional-use authorization and then on the holder of the product’s sanitary registration. The same right is restated in Article 17 of Ley 20.850. This is a statutory patient right, not an ethics-committee expectation or a best-efforts commitment, and breach is sanctionable under Article 111 G through Book Ten of the Código Sanitario.

    What is Ley 20.850 (Ley Ricarte Soto)?
    Ley 20.850 is the Chilean statute that created a universal financial protection system for high-cost diagnoses and treatments, promulgated 1 June 2015 and published 6 June 2015. It is named in posthumous tribute to journalist Luis Ricarte Soto Gallegos. Beyond the fund, its Article 34 inserted Titles V and VI into Book Four of the Código Sanitario, creating Chile’s clinical trial authorization regime (Arts. 111 A to 111 G) and its defective health-product liability regime (Arts. 111 H to 111 N). Most sponsors know the fund and miss the clinical trial chapter.

    What does Código Sanitario Art. 111 C require?
    It requires that, once a clinical trial ends, the holder of the special provisional-use authorization — and afterwards, where applicable, the holder of the product’s sanitary registration — provide the participant with continuity of treatment “sin costo para el paciente,” for the whole time that its therapeutic usefulness persists, in accordance with the study protocol. A second paragraph extends the duty to a registration holder that never held the provisional authorization or that acquired the registration later. There is no calendar limit and no cost-sharing exception in the text.

    Does Chile PTA apply to medical devices?
    Yes, on the face of the statute. Article 111 A states that the special provisional-use authorization is required for “todo producto farmacéutico o dispositivo médico,” and Title V is titled for pharmaceutical products and elements of medical use. Because Article 111 C attaches to the holder of that authorization, device sponsors are captured. The Ministry of Health may exempt low-risk device categories from the authorization requirement by supreme decree, so confirm the applicable decree for your class rather than assuming an exemption applies.

    Who pays for post-trial supply in Chile?
    The obligated party pays. Article 111 C says the treatment is provided “sin costo para el paciente,” and names the provisional-use authorization holder and then the sanitary-registration holder as the parties who must provide it. There is no provision allowing the cost to be shifted to the patient, the treating institution, FONASA or an isapre. Sponsors may allocate the economics contractually between themselves, a licensee or an acquirer, but that allocation does not change who Chilean law holds responsible to the patient.

    How long must sponsors provide post-trial access in Chile?
    For as long as therapeutic usefulness persists — “por todo el tiempo que persista su utilidad terapéutica.” Chile sets no fixed term, no five-year cap, and no automatic termination at commercial launch or reimbursement listing. That makes it materially more open-ended than Brazil, where Lei 14.874/2024 permits interruption five years after commercial availability. Because “utilidad terapéutica” is undefined in the statute, the study protocol referenced by Article 111 C becomes the practical instrument that defines when the obligation ends.

    What is the M&A diligence trap in Chile PTA?
    The second paragraph of Article 111 C binds the sanitary-registration holder “aun cuando no haya sido el titular de la autorización provisional o haya adquirido con posterioridad el registro sanitario.” The supply duty travels with the registration by operation of law. A buyer acquiring only a Chilean marketing authorization — with no trial contracts, no sponsor entity, no site agreements — can inherit an open-ended, free-of-charge obligation to patients it has never seen, arising from a trial it never ran. Standard reps and warranties rarely surface it, and standard product P&Ls never price it.

    What is ISP’s role in Chile PTA?
    The Instituto de Salud Pública grants the Article 111 A special provisional-use authorization (maximum one year, renewable for equal successive periods), maintains the public register of authorized human research, accredits research centers under Article 111 D, and fiscalizes protocols, informed consents, GCP and adverse-event notification. Its listed fee for prestación 4111035 is CLP $1,129,893 plus IVA. The ISP’s public register is the practical starting point for confirming whether a Chilean-registered product has a trial history that could trigger an Article 111 C tail.

    What is CENABAST and how does its exceptional-import route work?
    CENABAST is Chile’s Central de Abastecimiento, the public health supply and procurement agency. Under Article 15 of Ley 20.850, where a covered product’s registration is suspended, cancelled or lapsed, CENABAST may — with prior Ministry of Health authorization and where no priced alternative exists — exceptionally import and distribute it regardless of whether it holds sanitary registration, to guarantee treatment continuity. Article 31 lets it contract with multiple suppliers and request a provisional sanitary registration in shortage situations. Article 15 also makes registration holders, producers and importers civilly liable for failures of treatment continuity.

    Does the PTA obligation transfer with the marketing authorization?
    Yes. That is the explicit effect of Article 111 C’s second paragraph, and it is the single most commercially consequential sentence in Chile’s post-trial regime. Acquirers and in-licensees should treat the Chilean registration as carrying a potential supply liability, diligence the ISP research register and the seller’s Chilean trial history, quantify the number of patients still on treatment, and negotiate indemnities knowing that the statutory duty to the patient sits with whoever holds the registration.

    Sources

    • Ley Núm. 20.850, Ministerio de Salud, promulgated 1 June 2015 — Arts. 5, 15, 17, 31, 34, disposiciones transitorias: https://www.bcn.cl/leychile/navegar?idNorma=1078148
    • Código Sanitario (DFL 725), consolidated text — Arts. 99, 111 A, 111 B, 111 C, 111 D, 111 E, 111 F, 111 G, 111 H–111 N, 174: https://www.bcn.cl/leychile/navegar?idNorma=5595
    • Decreto 11 Exento, M. de Salud, 30 April 2025 (recital confirming Ley 20.850 published 6 June 2015): https://www.bcn.cl/leychile/navegar?idNorma=1212845
    • ISP prestación 4111035, provisional-use authorization for clinical study products: https://www.ispch.gob.cl/prestacion/4111035/
    • ISP, autorización excepcional sin registro sanitario (Art. 99 / D.S. 3/2010 Art. 21, prestación 4111036, SAFIS): https://www.ispch.gob.cl/anamed/medicamentos/autorizacion-excepcional-sin-registro-sanitario/
    • ISP, Estudios Clínicos: https://www.ispch.gob.cl/anamed/estudios-clinicos/
    • Resolución Exenta N° 173, 29 January 2024, “Guía de consideraciones generales para estudios clínicos” (ISP): https://www.bcn.cl/leychile/navegar?idNorma=1201301
    • Resolución Exenta N° 341, 7 April 2026 / Res. Ex. 2.050, “Guía de investigación clínica de dispositivos médicos en humanos. Buenas prácticas clínicas” (ISP): https://www.bcn.cl/leychile/navegar?idNorma=1223885 and https://www.ispch.gob.cl/wp-content/uploads/resoluciones/36444_2050-2026.pdf
    • CENABAST, “Ley Ricarte Soto: con nuevas facultades, CENABAST asegura disponibilidad de medicamentos”: https://www.cenabast.cl/ley-ricarte-soto-con-nuevas-facultades-cenabast-asegura-disponibilidad-de-medicamentos/
    • Superintendencia de Salud, Ley Ricarte Soto orientation page: https://www.superdesalud.gob.cl/tax-temas-de-orientacion/ley-ricarte-soto-6088/
    • ChileAtiende, Ley Ricarte Soto: https://www.chileatiende.gob.cl/fichas/38873-ley-ricarte-soto
    • Academia Chilena de Medicina, declaration on Title V of Ley 20.850 and its draft reglamento, Revista Médica de Chile: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000300013

  • Post-trial access in Latin America: the operator’s map

    Ten Latin American countries legally require a trial sponsor to keep supplying the investigational product after the study closes. Three more address post-trial continuation in binding instruments with weak or unassigned duties. Seven impose nothing. If your Phase 3 has LATAM sites, that distinction is a line item, not an ethics footnote.

    We built this map because the region is now diverging fast. Brazil enacted a statute in 2024 and its regulation in 2025. Honduras went from zero to a mandate in February 2026. Panama replaced its research decree in April 2026. Meanwhile most global vendor and law-firm summaries still cite instruments that have been repealed, and several repeat citation errors that a regulator would catch on the first review cycle.

    Where the mandates actually are

    Across 20 jurisdictions, the classification breaks down as follows.

    Binding statutory mandate (10): Argentina, Brazil, Chile, Peru, Ecuador, Costa Rica, Guatemala, Honduras, Nicaragua, Panama. Each has a law, decree, resolution or ministerial normativa that obliges continued provision of the investigational product after the trial ends.

    Binding instrument, weak or unassigned duty (3): Uruguay, Bolivia, Venezuela. Venezuela’s Buenas Prácticas Clínicas §6.12.1 requires the sponsor only to “procurar… la provisión del tratamiento” after the trial — endeavour, not provide (INHRR). Uruguay’s Decreto 158/019 Anexo numeral 24 says participants “deben tener la certeza de que contarán con los beneficios demostrados” but names no obligor at all (IMPO). Bolivia’s Art. 99 routes continuation entirely into the compassionate-use chapter, requiring per-patient DINAMED authorization (AGEMED).

    No mandate (7): Mexico, Colombia, Paraguay, El Salvador, Dominican Republic, Cuba, Puerto Rico. In each case we read the operative clinical-trial instrument and it contains no post-trial supply obligation.

    The comparative matrix

    Country Mandate status Primary instrument Cost allocation Import mechanism
    Argentina Binding statute Disp. ANMAT 12792/2016; GCP base reset by Disp. 7516/2025 Sponsor, free to participant, site and payer (Art. 3(g)) Dedicated PTA import expediente to ANMAT–DERM, valid 12 months (Art. 4); physical import via INAME (Art. 5)
    Brazil Binding statute Lei 14.874/2024 Arts. 30–37 + Decreto 12.651/2025 Art. 31 Sponsor (Lei Art. 31 §4); free supply (Decreto Art. 31) ANVISA authorization + import licence under RDC 38/2013
    Chile Binding statute Ley 20.850 Art. 17; Cód. Sanitario Art. 111 C “Sin costo para el paciente”; duty on provisional-authorization holder, then registration holder ISP special provisional-use authorization (Art. 111 A); CENABAST exceptional import
    Peru Binding statute DS 021-2017-SA Arts. 115–118 Sponsor-funded, provided free (Arts. 40(p), 89) OGITT extension trial or case-by-case ANM/DIGEMID authorization (Art. 116) with a seven-document set (Art. 117)
    Panama Binding statute Decreto Ejecutivo 21/2026 Art. 68, Gaceta Oficial 30510-C, 23 Apr 2026 Investigators and sponsors co-obligated to ensure access; cost not stated verbatim Extension of the trial import permit for exclusive participant use (Art. 68); RESEGIS registration + DNFD authorization (Art. 99)
    Ecuador Binding statute AM 00069-2024 Arts. 80–81, 95(c) Sponsor or legal representative, “entrega gratuita” (Art. 80) No PTA-specific route; general ARCSA import authorization
    Costa Rica Binding statute Ley 9234 Arts. 28, 53(k) Sponsor, free, “mientras lo requieran” None identified in the statute for post-trial product
    Guatemala Binding statute (instrument version unconfirmed) AM 82-2019 Art. 64; MSPAS index lists AM 206-2021 Supply “podrá ser solicitada al patrocinador” — request-driven, not automatic Compassionate-use authorization by the DRCPFA (Art. 65)
    Honduras Binding statute (new) Acuerdo 0256-ARSA-2025 Art. 63 Sponsor or legal representative, “sin costo” (Art. 63) Extension trial or compassionate use (Art. 63); special ARSA import authorization (Art. 86)
    Nicaragua Binding statute Normativa-166 Cap. VI num. 16 Sponsor obliged; free-of-charge stated for the trial phase only General trial import rules; no PTA route
    Uruguay Binding guidance Decreto 158/019 Anexo num. 24 No obligor named n.a.
    Bolivia Binding guidance Norma para Estudios Clínicos Art. 99 → Arts. 74–76 Not allocated post-trial Per-patient DINAMED compassionate-use authorization
    Venezuela Binding guidance Normas de BPC §§5.4.5, 6.12.1 Free during trial only; post-trial duty is “procurar” None described
    Mexico No mandate for product supply NOM-012-SSA3-2012 §11.2.2 Investigator must arrange continued “tratamiento y cuidados” — not IP supply n.a.
    Colombia No mandate Res. 2378/2008 n.a. n.a.
    Paraguay No mandate Resol. DINAVISA 238/2024 n.a. n.a.
    El Salvador No mandate Lineamientos Técnicos, Ac. Ejec. 1530 (2025) n.a. n.a.
    Dominican Republic No mandate Manual CONABIOS, 2ª ed. n.a. — §7.1 gives an information right only n.a.
    Cuba No mandate BPC en Cuba (CECMED) n.a. — §4.3.2 covers adverse-event medical care only n.a.
    Puerto Rico (US) No mandate 21 CFR 312 Subpart I n.a. — permissive expanded-access framework n.a. (US customs territory)

    Why this is a closing cost, not an ethics footnote

    A sponsor that runs sites in Brazil, Chile, Peru, Panama and Argentina and then closes the study has, in five jurisdictions, a legally enforceable duty to keep shipping product to responders — free of charge, under separate authorizations, for a period the sponsor does not control.

    Brazil’s Ministry of Health states the position without hedging: continued post-study treatment “não é uma expectativa, mas um dever legal, aplicável desde o planejamento da pesquisa até o período pós-estudo” (INAEP FAQ). That duty is priced nowhere in a standard Phase 3 budget. It requires a cohort-scale filing distinct from the trial dossier, an import authorization with its own clock, GDP-compliant cold chain for as long as the cohort persists, and pharmacovigilance reporting after database lock.

    The obligation also survives corporate events. Chile’s Código Sanitario Art. 111 C states the duty “afectará al titular del registro sanitario, aun cuando no haya sido el titular de la autorización provisional o haya adquirido con posterioridad el registro sanitario” (BCN). Buy a Chilean registration and you buy the free-supply obligation attached to it. That belongs in diligence, not in a site-activation checklist.

    The five strongest sponsor obligations

    Brazil. Lei 14.874/2024 Art. 30 requires the sponsor and investigator to file a post-study access plan with the CEP before the trial starts. Art. 31 §4 puts the cost on the sponsor. Art. 33 permits interruption only on listed grounds, including the “transcurso do prazo de 5 (cinco) anos, contado da disponibilidade comercial do medicamento experimental no País.” Decreto 12.651/2025 Art. 31 restates the free-supply duty whenever the investigator judges the product the best therapeutic alternative. Full detail in our Brazil post-trial access pillar.

    Chile. Art. 111 C obliges continuity “sin costo para el paciente… por todo el tiempo que persista su utilidad terapéutica” — no commercialization endpoint, no five-year cap. See the Chile Ley 20.850 analysis.

    Panama. Article 68 of Decreto Ejecutivo 21/2026 (Gaceta Oficial 30510-C, 23 April 2026) reads: “Los investigadores y patrocinadores deben asegurar a todos los participantes el acceso al producto, siempre que se haya comprobado el beneficio clínico o de salud pública de la intervención durante el estudio; hasta su comercialización en el país.” It then requires the sponsor to apply for “una extensión del permiso de importación del producto utilizado durante la investigación para uso exclusivo de los participantes.” The decree entered into force on promulgation under Art. 105. Detail in the Panama Decreto 21/2026 pillar.

    Argentina. Disposición ANMAT 12792/2016 is the only instrument in the region that is purely a post-trial access import procedure. Art. 3(g) requires a sworn sponsor declaration that supply will be “sin costo alguno para el participante, el establecimiento asistencial o su cobertura de salud” — note that the site and the payer are named, not just the patient. Art. 4 gives the DERM authorization a 12-month validity. Art. 2 excludes authorized extension studies, which run on a different track. See the Argentina Disposición 12792 pillar.

    Peru. DS 021-2017-SA is the best-drafted operational regime in the region: Art. 115 defines the obligation and its trigger conditions, Art. 116 names two authorization routes (OGITT extension trial or case-by-case ANM/DIGEMID authorization), Art. 117 lists the documents, Art. 118 assigns post-access pharmacovigilance. Art. 40(p) makes it a sponsor duty. See the Peru DS 021-2017-SA pillar.

    Where the duty reaches devices

    Most LATAM post-trial provisions were drafted for medicines. Four jurisdictions reach hardware textually.

    Costa Rica is the clearest. Ley 9234 Art. 53(k) obliges the sponsor to provide, free of charge and after the study concludes, “el medicamento, dispositivo o procedimiento que ha sido objeto de investigación,” with four exhaustive exits — including a reasoned treating-physician resolution filed in the record and communicated to the CEC within three working days. Art. 28 sets the duration at “mientras lo requieran.”

    Brazil reaches devices through Lei 14.874/2024 Art. 37: “Aplicar-se-ão aos produtos e dispositivos médicos e aos produtos de terapias avançadas experimentais… as disposições deste Capítulo, no que couber.” Chile reaches them through Código Sanitario Art. 111 A, which covers “los productos farmacéuticos y los elementos de uso médico.” Peru reaches them through the definition of producto en investigación in Art. 2.1.36.

    Ecuador does not. AM 00069-2024 is a reglamento for medicines and processed natural medicinal products, so a device sponsor’s Ecuadorian exposure runs through ethics-committee expectations and the informed consent, not through Arts. 80–81.

    What changed between 2024 and 2026

    Honduras added a mandate. Acuerdo 0256-ARSA-2025 Art. 63 defines post-trial access as “la entrega sin costo por parte del patrocinador o su representante legal,” even where the product has no Honduran sanitary registration, subject to three cumulative conditions. Published in La Gaceta on 28 January 2026, in force 30 days later. The predecessor Acuerdo 041-2020 had no post-trial provision at all. Read Art. 63 alongside Art. 18 numeral 5, which softens the duty to facilitating access “cuando el patrocinador lo considere” — a real internal tension, and a reason not to treat Honduras as equivalent to Brazil.

    Panama replaced its research decree. Decreto Ejecutivo 21/2026 reglamenta Titles III and IV of Ley 84 de 14 de mayo de 2019 and entered into force on promulgation, 23 April 2026. Its Art. 104 repeals Decreto Ejecutivo 1843 of 2014, Decreto Ejecutivo 6 of 2015 and Resolución 390 of 2003.

    Ecuador deleted its endpoint. AM 00069-2024 Art. 80 states the free-supply duty with no termination point. The repealed AM 0075-2017 had capped it: Art. 39(w) ran only “hasta que el producto se comercialice en el país” (MSP Ecuador). Art. 81 narrowed the trigger to three cumulative conditions while the duration became open-ended. Almost nobody has flagged that trade.

    Brazil completed a two-step build. Statute in 2024, regulation in 2025, with further INAEP guidance promised by Decreto 12.651/2025 Art. 31 §2.

    Argentina reset its GCP base. Disposición 7516/2025 took effect 1 December 2025 (Art. 8). Its Art. 7 repealed Disposiciones 6677/10, 4008/17, 9929/19 and 2172/25 plus Circulares 0001/11 and 004/18. Disp. 12792/2016 is absent from that repeal list, so the post-trial import procedure stands — but the substantive continuity duty moved into the new GCP annex, and sponsors are filing against instruments that no longer exist. The legal architecture of LATAM PTA piece works through how the obligation layer and the import layer interact.

    Colombia: no binding post-trial access statute

    We read Resolución 2378 de 2008 and Resolución 8430 de 1993 in full, checking expressly for post-trial supply language. Neither contains any. Res. 8430/1993 allocates only harm-related costs — Art. 13 medical care for research-related injury, Art. 15(j) treatment availability and indemnification, Art. 15(k) additional costs against the research budget.

    That makes Colombia a cost-certainty jurisdiction: no statutory tail obligation, no separate post-trial filing, no open-ended supply exposure. It does not make post-trial access impossible. A sponsor that wants to continue supplying responders in Colombia can run a voluntary continuity program on its own initiative, handled through the ethics committee, the informed consent and the general product import rules. The exposure is contractual and reputational rather than statutory, which means it has to be allocated in the CRO and site agreements rather than assumed away.

    Mexico sits in an adjacent position and is routinely misdescribed. NOM-012-SSA3-2012 §11.2.2 obliges “el investigador principal” to arrange continuation of “el tratamiento y cuidados” to prevent withdrawal effects. That is an investigator duty about care, not a sponsor duty to supply the investigational product.

    What sponsors get wrong

    Citing repealed instruments. Argentina’s Disp. 6677/2010, which historically carried the continuity obligation, is repealed. Ecuador’s AM 0075-2017 is repealed. Honduras’s Acuerdo 041-2020 is revoked in its entirety. Panama’s Decreto Ejecutivo 1843/2014 and 6/2015 are repealed. Filings and legal memos still quote all of them.

    The “Ley 419/2023” error. Panama’s medicines statute is Ley 419 of 1 February 2024, not 2023 — and it is a commercial-medicines law, not the post-trial access instrument. The binding post-trial duty sits in Decreto Ejecutivo 21/2026 Art. 68, under Ley 84 of 2019. Getting this wrong signals to a Panamanian reviewer that the filer has not read the current framework.

    Treating Argentina’s RAEM as post-trial access. Disposición 4616/2019 approves the Régimen de Accesibilidad de Excepción a Medicamentos: an individual-patient exceptional import route with 90-day, 180-day and one-year quantity windows (Boletín Oficial). It contains no reference to clinical trials or post-trial access. Filing a trial cohort through RAEM means one expediente per patient, per renewal, on the wrong legal basis. Cohort post-trial access in Argentina runs on Disp. 12792/2016.

    Assuming an obligation implies a pathway. Costa Rica mandates continued free provision of the device or medicine under Art. 53(k), but Art. 55 addresses importation only before an approved study begins. No post-trial import route is identified in the statute. Ecuador and Nicaragua have the same shape. The obligation is real; the mechanism has to be constructed.

    The fastest route to compliance

    For a sponsor closing a multi-country LATAM Phase 3, the sequence that works is: classify each participating country into mandate / soft / none using the operative current instrument; identify which mandate countries require a filing distinct from the trial dossier (Argentina, Brazil, Panama, Peru at minimum); confirm whether your product class is textually in scope, which matters most for devices; establish who the legal importer of record will be in each country, since the trial import authorization frequently expires with the trial; and only then estimate cohort size, duration and cold-chain cost. Countries with no mandate still need a documented position, because the ethics committee and the informed consent will ask.

    Working on a LATAM post-trial access program? bioaccess® is a US-headquartered, LATAM-native operator running regulatory, importadora, and 2–8 °C GDP cold-chain functions directly across the region. If you’re evaluating PTA feasibility in Argentina, Brazil, Chile, Peru, Panama, Costa Rica or elsewhere in Latin America, contact Julio Martinez-Clark, Co-Founder & CEO, at jmclark@bioaccessla.com or +1 (954) 903-7210. More at bioaccessla.com/roadmap.

    Frequently Asked Questions

    Which Latin American countries require post-trial access?
    Ten jurisdictions impose a binding statutory duty: Argentina, Brazil, Chile, Peru, Ecuador, Costa Rica, Guatemala, Honduras, Nicaragua and Panama. Three more — Uruguay, Bolivia and Venezuela — address post-trial continuation in binding instruments but with weak verbs, no named obligor, or routing into per-patient compassionate use. Seven impose nothing: Mexico, Colombia, Paraguay, El Salvador, the Dominican Republic, Cuba and Puerto Rico. The classification depends on reading the operative current instrument, not a secondary summary, because five of these countries changed their framework between 2024 and 2026.

    Which LATAM country has the strongest post-trial access mandate?
    Brazil. Lei 14.874/2024 Art. 30 requires a post-study access plan to be filed with the ethics committee before the trial begins, Art. 31 §4 assigns the cost to the sponsor, and Art. 33 permits interruption only on listed grounds — one of which is the passage of five years from the product’s commercial availability in Brazil. Decreto 12.651/2025 Art. 31 restates the free-supply duty. Brazil’s Ministry of Health describes this as a legal duty rather than an expectation. Chile is the closest runner-up because Art. 111 C has no endpoint at all and the obligation follows the sanitary registration to any subsequent holder.

    Does post-trial access in LATAM apply to medical devices or only drugs?
    Both, in four jurisdictions. Costa Rica’s Ley 9234 Art. 53(k) is the most explicit, obliging free post-study provision of “el medicamento, dispositivo o procedimiento.” Brazil extends its post-trial chapter to devices and advanced therapies through Lei 14.874/2024 Art. 37. Chile’s Código Sanitario Art. 111 A covers “elementos de uso médico.” Peru’s definition of producto en investigación in DS 021-2017-SA Art. 2.1.36 includes devices. Ecuador’s AM 00069-2024 does not cover devices. Argentina’s Disp. 12792/2016 covers products and “materiales” without using the word dispositivo médico, so device coverage there is inferential.

    Which LATAM countries do NOT require post-trial access?
    Mexico, Colombia, Paraguay, El Salvador, the Dominican Republic, Cuba and Puerto Rico. Colombia’s Resoluciones 2378/2008 and 8430/1993 contain no post-trial supply obligation; Res. 8430/1993 allocates only harm-related costs. Mexico’s NOM-012-SSA3-2012 §11.2.2 imposes a continuity duty on the principal investigator covering treatment and care, not on the sponsor to supply the investigational product. Notably, both Paraguay (2024) and El Salvador (2025) rewrote their research frameworks in this window and declined to add a post-trial provision, which cuts against the assumption that the whole region is converging on mandatory access.

    What changed in LATAM post-trial access regulation in 2024-2026?
    Five substantive moves. Brazil completed a two-step build with Lei 14.874/2024 and Decreto 12.651/2025. Ecuador’s AM 00069-2024 repealed AM 0075-2017 and deleted the “until commercialized in the country” endpoint, converting a bounded duty into an open-ended one. Argentina’s Disposición 7516/2025 took effect 1 December 2025 and repealed Disp. 6677/10 among others, resetting the GCP base while leaving the 2016 post-trial import procedure standing. Honduras moved from no mandate to a binding mandate via Acuerdo 0256-ARSA-2025 Art. 63, in force from late February 2026. Panama’s Decreto Ejecutivo 21/2026 entered into force 23 April 2026 with a binding post-trial duty in Art. 68.

    What is the difference between cohort PTA (Argentina) and individual expanded access (RAEM)?
    They are separate legal regimes with separate instruments. Post-trial access under Disposición ANMAT 12792/2016 is a cohort-level procedure: one expediente covering the named participants from an ANMAT-authorized trial, approved by the ethics committee, filed with the Dirección de Evaluación y Registro de Medicamentos, with a 12-month import authorization under Art. 4. The Régimen de Accesibilidad de Excepción a Medicamentos under Disposición 4616/2019 is an individual-patient exceptional import route with 90-day, 180-day and one-year quantity limits, and it makes no reference to clinical trials. Using RAEM for a trial cohort produces per-patient filings on the wrong basis.

    Who pays for post-trial access in Latin America?
    The sponsor, in every country where the duty is clearly allocated. Brazil’s Lei 14.874/2024 Art. 31 §4 puts the supply on the sponsor. Peru’s DS 021-2017-SA Art. 89 requires products to be sponsor-financed and provided free. Costa Rica’s Ley 9234 Art. 53(k) and Ecuador’s AM 00069-2024 Art. 80 both name the sponsor. Chile’s Art. 111 C places the duty on the provisional-authorization holder and then the registration holder. Argentina goes furthest: Disp. 12792/2016 Art. 3(g) requires a sworn declaration that supply carries no cost to the participant, the treating institution or the health coverage. Uruguay, Bolivia, Nicaragua and Honduras leave the cost-bearer partly or wholly unstated.

    How does a sponsor find a qualified PTA operator in Latin America?
    Test three capabilities separately. First, regulatory: can the operator file the country-specific post-trial authorization itself, naming the correct current instrument and article, rather than subcontracting it blind. Second, importation: can it act as legal importer of record after the trial import authorization lapses, which it does in several countries. Third, distribution: can it hold and ship the product under 2–8 °C GDP conditions for the life of the cohort, with pharmacovigilance reporting after database lock. Global post-trial supply vendors market the service regionally without naming Latin American countries or local filing capability on their public pages, so ask for the specific article and the specific authorizing office.

    What is the fastest route to compliance for a sponsor closing a multi-country LATAM Phase 3?
    Start from the operative instrument in each participating country, not from a regional summary. Classify each country as binding mandate, weak instrument or no mandate; determine which mandate countries require a filing distinct from the trial dossier — Argentina, Brazil, Panama and Peru at minimum; confirm your product class is textually in scope, which is the decisive question for devices; appoint a legal importer of record in each country because trial import authorizations frequently expire with the trial; then size the cohort, the duration and the cold chain. Countries with no mandate still need a documented, defensible position for the ethics committee.

    Sources

    • Argentina — Disposición ANMAT 12792/2016: https://www.boletinoficial.gob.ar/detalleAviso/primera/154162/20161117
    • Argentina — Disposición ANMAT 7516/2025: https://www.boletinoficial.gob.ar/detalleAviso/primera/332695/20251009
    • Argentina — Disposición ANMAT 4616/2019 (RAEM): https://www.boletinoficial.gob.ar/detalleAviso/primera/208794/20190604
    • Brazil — Lei nº 14.874/2024: https://www.planalto.gov.br/ccivil_03/_ato2023-2026/2024/lei/l14874.htm
    • Brazil — Decreto nº 12.651/2025: https://www2.camara.leg.br/legin/fed/decret/2025/decreto-12651-7-outubro-2025-798105-publicacaooriginal-176652-pe.html
    • Brazil — ANVISA RDC nº 38/2013: https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000038&seqAto=000&valorAno=2013&orgao=RDC/DC/ANVISA/MS&codTipo=&desItem=&desItemFim=&cod_menu=1696&cod_modulo=134&pesquisa=true
    • Brazil — Ministério da Saúde / INAEP FAQ on acesso pós-estudo: https://www.gov.br/saude/pt-br/composicao/orgaos-colegiados/inaep/faq/faq/acesso-pos-estudo/o-acesso-fornecimento-pos-estudo-e
    • Chile — Ley 20.850 and Código Sanitario Arts. 111 A–111 C: https://www.bcn.cl/leychile/navegar?idNorma=1078148
    • Peru — Reglamento de Ensayos Clínicos, DS 021-2017-SA: https://ensayosclinicos-repec.ins.gob.pe/images/Reglamento_de_EC.pdf
    • Panama — Decreto Ejecutivo No. 21 de 23 de abril de 2026, Gaceta Oficial Digital No. 30510-C (Arts. 68, 99, 104, 105); primary text read from the Gaceta Oficial PDF
    • Panama — Ley 419 de 1 de febrero de 2024 (medicamentos): https://www.minsa.gob.pa/sites/default/files/normatividad/ley-419-de-2024-ley-de-medicamentos.pdf
    • Ecuador — Acuerdo Ministerial 00069-2024: https://www.espoch.edu.ec/wp-content/uploads/2025/10/ac-00069-2024_dic_31_compressed_1-1.pdf
    • Ecuador — Acuerdo Ministerial 0075-2017 (repealed): https://www.salud.gob.ec/wp-content/uploads/2022/09/A.M.-0075-REGLAMENTO-ENSAYOS-CLINICOS-1.pdf
    • Costa Rica — Ley N.º 9234, Ley Reguladora de Investigación Biomédica: https://documentos.una.ac.cr/bitstream/handle/unadocs/5670/Texto%20Completo%20Norma%209234.pdf?sequence=1&isAllowed=y
    • Guatemala — Acuerdo Ministerial 82-2019: https://medicamentos.mspas.gob.gt/phocadownload/Acuerdo%20Ministerial%2082-2019.pdf
    • Guatemala — MSPAS legislación vigente index (AM 206-2021): https://medicamentos.mspas.gob.gt/index.php/legislacion-vigente/acuerdos
    • Honduras — Acuerdo No. 0256-ARSA-2025: https://www.tsc.gob.hn/web/leyes/Acuerdo-0256-ARSA-2025.pdf
    • Nicaragua — Normativa-166, Norma para la Regulación de Ensayos Clínicos: https://www.minsa.gob.ni/sites/default/files/2022-10/Norma%20de%20Ensayos%20Clinicos.11833.pdf
    • Uruguay — Decreto N° 158/019, Anexo: https://www.impo.com.uy/bases/decretos-originales/158-2019/8
    • Bolivia — Norma para Estudios Clínicos (AGEMED): https://www.agemed.gob.bo/archivos_agemed/ensayosclinicos/001-2021.pdf
    • Venezuela — Normas de Buena Práctica Clínica (INHRR): https://inhrr.gob.ve/pdf/pdf_jr/JR-1311-2013.pdf
    • Mexico — NOM-012-SSA3-2012: https://sidof.segob.gob.mx/notas/docFuente/5284148
    • Colombia — Resolución 2378 de 2008: https://www.ins.gov.co/Normatividad/Resoluciones/RESOLUCION%202378%20DE%202008.pdf
    • Colombia — Resolución 8430 de 1993: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/de/dij/resolucion-8430-DE-1993.PDF
    • Paraguay — Resolución DINAVISA 238/2024: https://dinavisa.gov.py/wp-content/uploads/2024/10/2.-Requisitos-de-Ensayos-Clinicos.-Resol.-238_2024.pdf
    • El Salvador — Lineamientos Técnicos para la Investigación en Salud, Acuerdo Ejecutivo 1530 (2025): https://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientostecnicosparalainvestigacionensalud-Acuerdo-Ejecutivo-1530-29052025_v1.pdf
    • Dominican Republic — Manual de Normas y Procedimientos Operativos, CONABIOS: https://conabios.gob.do/wp-content/uploads/2025/02/1.Manual-de-Normas-y-Procedimientos-Operativos-V2-13-02.pdf
    • Cuba — Buenas Prácticas Clínicas en Cuba (CECMED): https://www.cecmed.cu/sites/default/files/adjuntos/Reglamentacion/Dir_BPC.pdf
    • United States / Puerto Rico — 21 CFR 312.310 (Expanded Access, Subpart I): https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-I/section-312.310
    • FDA — Expanded Access training materials: https://www.fda.gov/media/193381/download

  • 10 ISP Chile Registration Support Companies for Clinical Research

    10 ISP Chile Registration Support Companies for Clinical Research

    Introduction

    The landscape of clinical research in Chile is rapidly evolving, with numerous companies stepping up to support innovators in navigating this complex field. As the demand for efficient and effective clinical trials grows, understanding which organizations can provide the necessary expertise becomes crucial. This article explores ten prominent ISP registration support companies that are reshaping the clinical research environment in Chile, offering invaluable services that streamline processes and enhance outcomes. How can these organizations help researchers overcome the unique challenges of conducting studies in this vibrant market?

    bioaccess: Leading CRO for Accelerated Clinical Research Services in Latin America

    bioaccess® stands out as a leading (CRO) in Latin America, specializing in . Concentrating on the Medtech, Biopharma, and Radiopharma sectors, bioaccess® capitalizes on Colombia’s competitive advantages, which include:

    • Substantial compared to North America and Western Europe
    • A rapid regulatory review process that enables ethical approvals within just 4-6 weeks

    This swift turnaround is pivotal, allowing research studies to commence promptly and providing a significant edge over traditional markets. Additionally, Colombia boasts a , ranked among the best globally, and a diverse patient pool of over 50 million, further enhancing bioaccess®’s capability to deliver efficient . Furthermore, the , such as:

    • 100% tax deductions
    • Considerable government grants

    amplify the attractiveness of conducting experiments in the region. Their unwavering commitment to high-quality, cost-effective research services has established them as a trusted partner for innovators eager to expedite their clinical trials and bring medical breakthroughs to market more swiftly.

    The central node represents bioaccess® as a leading CRO, while the branches illustrate its key advantages. Each sub-branch provides specific details related to the main points, helping readers understand how bioaccess® stands out in clinical research.

    Pharmalex: Comprehensive Regulatory Affairs and Quality Assurance Services

    Pharmalex offers a comprehensive suite of compliance and services specifically designed for the pharmaceutical and biotechnology sectors. Their expertise spans the entire , empowering clients to adeptly .

    With a committed team of , Pharmalex ensures adherence to all pertinent regulations, facilitating smooth interactions with . This unwavering throughout the research process, which is critical for achieving successful .

    Such a focus on quality not only enhances the integrity of but also accelerates the path to market, enabling innovators to deliver their groundbreaking products to patients more efficiently.

    The center represents Pharmalex's overall services, with branches detailing key areas of expertise. Each color-coded section shows how different services interconnect and their importance in the pharmaceutical and biotechnology sectors.

    Celerion: Specialized Clinical Research Services for Biopharmaceuticals

    Celerion stands as a prominent authority in specialized medical research services, particularly within the biopharmaceutical sector. By concentrating on early-stage studies, Celerion offers a comprehensive array of services, including:

    • pharmacokinetics
    • pharmacodynamics
    • bioanalytical support

    Their expert team is dedicated to providing high-quality data that informs drug development decisions, ensuring that clients can advance their products efficiently through the research process.

    In conjunction with Celerion’s offerings, bioaccess delivers extensive in Colombia, empowering medtech and biopharma startups to expedite their . With capabilities such as:

    • compliance reviews
    • experimentation setup
    • import permits
    • reporting

    This platform facilitates faster patient enrollment—up to 50% quicker than Western locations—and substantial cost savings of $25K per patient with FDA-ready data. This commitment to innovation and compliance positions both Celerion and bioaccess as leaders in the .

    The central node represents Celerion's overall focus on clinical research, with branches showing the specific services they provide, and further branches detailing the offerings from bioaccess. Each color-coded section helps you quickly identify different categories of services.

    PRA Health Sciences: Global Leader in Clinical Research and Regulatory Support

    bioaccess™ stands as a leader in advancing across Latin America, offering a comprehensive suite of services that encompasses:

    1. Site selection

    Their expertise ensures that assessments are organized efficiently, adhering to , which are crucial for achieving successful outcomes. This includes a thorough review and feedback on study documents to meet country-specific requirements, as well as managing the import permit process for investigational devices.

    In collaboration with organizations such as Caribbean Health Group, bioaccess™ is establishing Barranquilla as a premier location for medical research, with the backing of Colombia’s Minister of Health. A significant demonstration of their influence is the of the Flow-Screw device by Flow-FX, which aims to revolutionize antibiotic delivery in orthopedic surgery. This trial exemplifies bioaccess™’s commitment to innovation and regulatory excellence as they navigate the complexities of research to enhance patient outcomes.

    Furthermore, their partnership with GlobalCare Clinical Trials has resulted in , while maintaining a 95% retention rate. As we look to 2025, bioaccess™ continues to be a vital player in the research landscape, driving economic growth and healthcare advancements through their dedicated services.

    The central node represents bioaccess™'s core services. Each branch highlights a specific service, allowing you to see how they contribute to the overall mission of improving clinical research and patient outcomes.

    QuintilesIMS: Integrated Services for Clinical Development and Regulatory Affairs

    bioaccess® offers that encompass the entire development process, specifically tailored for innovators in Medtech, Biopharma, and Radiopharma. With a robust emphasis on , bioaccess® ensures extensive support throughout . By leveraging advanced technologies and a profound understanding of the healthcare landscape, bioaccess® aids clients in navigating the complexities of research, guaranteeing that studies are executed efficiently and effectively. Notably, bioaccess® secures in a mere 4-6 weeks and achieves enrollment rates that are 50% faster than traditional markets, resulting in with .

    Furthermore, bioaccess® utilizes pre-qualified networks and facilitates simultaneous submissions, enhancing the efficiency of the research process. This commitment to innovation and excellence positions bioaccess® as a dependable ally in the evolving trial environment.

    To maximize success, companies should contemplate integrating bioaccess®’s rapid approval processes and into their development plans, particularly concerning , including:

    1. Pilot Studies
    2. Pivotal Studies

    across LATAM, Eastern Europe, and Australia.

    This flowchart shows how bioaccess® supports various types of clinical studies and highlights the benefits of their services. Each type of study is linked to the key advantages that bioaccess® provides, making it clear how they enhance the research process.

    Medpace: Full-Service Clinical Research Organization with Regulatory Expertise

    The organization distinguishes itself as a comprehensive research entity, offering a diverse array of services tailored for biopharmaceutical and medical device firms. Their expertise encompasses:

    • Study setup
    • Import permits
    • Monitoring

    This ensures that clients receive . Notably, the organization’s commitment to is exemplified by their innovative strategy, which facilitates approval in a mere 6-8 weeks—substantially faster than the typical 6-12 months observed in the US and EU. This strategic focus on compliance knowledge positions the organization as a pivotal player in navigating the complexities of medical research, ultimately enhancing the prospects for . With a team of seasoned experts, the company consistently delivers exceptional outcomes that are vital for , effectively addressing the challenges faced by medical device startups in research studies, including , recruitment issues, and the need for efficient .

    The center node represents Medpace, and each branch shows a specific service they provide. This structure helps you understand how each service fits into their overall mission to support medical research.

    ICON plc: Global Provider of Drug Development Solutions and Regulatory Services

    A leading provider of trial management solutions, specializing in enhancing medical device studies through a comprehensive range of services. Their expertise encompasses:

    1. Reporting

    This enables clients to navigate the complexities of with efficiency. In addition to these services, the company delivers thorough review and feedback on study documents to ensure adherence to national regulations and manages the import permit process for investigational devices.

    With a strategic focus on Colombia, the organization leverages the country’s , including cost efficiency—yielding savings exceeding 30% compared to trials in North America and Western Europe—and expedited regulatory processes, with IRB/EC and INVIMA approvals typically completed within 90-120 days.

    This strategic approach not only accelerates patient enrollment by up to 50% but also provides , resulting in significant savings of $25K per patient. The organization’s commitment to quality and compliance is evident in their rigorous methodologies, empowering clients to achieve favorable results across diverse markets.

    The center of the map represents ICON plc's services, with branches leading to specific areas of expertise and strategic advantages. Each color-coded branch shows different aspects of their offerings and how they help clients in clinical research.

    Syneos Health: Integrated Biopharmaceutical Solutions for Clinical Development

    The organization stands as a fully integrated biopharmaceutical solutions provider, delivering a comprehensive array of services designed to facilitate development, particularly in Chile and Argentina. Their expertise spans:

    1. Site selection
    2. Experimental setup
    3. Import permits
    4. Meticulous reporting, which includes thorough review and feedback on study documents alongside the nationalization of investigational devices

    This commitment to innovation and excellence is reflected in their approach to , enabling clients to enroll cardiology or neurology groups 50% faster than their Western counterparts, resulting in of $25,000 per patient with FDA-ready data. The organization’s seasoned team is dedicated to guiding clients through regulatory challenges and expediting approval processes, ensuring thorough support throughout the research journey. To explore how bioaccess can assist in , schedule a meeting today.

    The center represents Syneos Health's commitment to integrated solutions, with branches showing individual services. Each branch allows you to explore specific areas of expertise that contribute to efficient clinical development.

    KCR: Innovative Clinical Research Services Tailored for Latin America

    KCR stands as a dedicated to providing tailored services for studies in Latin America. Their extensive expertise spans:

    1. Site selection
    2. Compliance assistance

    This empowers clients to navigate the complexities of . KCR’s unwavering commitment to quality and compliance is evident in their rigorous approach to , enabling clients to . With a seasoned team focused on delivering high-quality results, KCR drives product approvals and fosters advancement in .

    At the center is KCR, showcasing their innovative approach to clinical research. Each branch represents a key service they offer, helping clients navigate the complexities of research in Latin America.

    CROMSOURCE: Global CRO with Local Expertise in Clinical Trials and Regulatory Affairs

    Bioaccess stands as a prominent (CRO) with a global footprint, seamlessly integrating extensive international experience with localized expertise in studies and compliance matters. Our comprehensive services span all phases of , encompassing:

    1. Feasibility studies

    We specialize in advancing , ensuring strict adherence to country-specific requirements while facilitating trial setup, including ethics committee approvals and import permits.

    With an unwavering commitment to , Bioaccess empowers clients to achieve successful outcomes through meticulous and detailed reporting on study status, inventory, and adverse events. Our seasoned team is dedicated to delivering exceptional results that drive product approvals, positioning Bioaccess as a trusted partner within the industry. Furthermore, conducting clinical trials in Colombia presents competitive advantages, such as cost efficiency and expedited regulatory processes, significantly enhancing the value of our offerings.

    In the evolving Medtech landscape, Bioaccess plays a crucial role in addressing key challenges faced by clients, fostering collaboration that is vital for navigating the complexities of clinical research. As we move forward, we invite you to consider how our expertise can support your needs and drive your projects to success.

    The center represents Bioaccess's services, with branches detailing specific offerings in clinical trials, each indicating how they contribute to successful project outcomes.

    Conclusion

    The landscape of clinical research in Chile is significantly enriched by the presence of numerous specialized support companies, each offering unique advantages tailored to the needs of innovators in the biopharmaceutical and medical device sectors. Key players such as bioaccess, Pharmalex, and Celerion not only streamline the research process but also ensure compliance with local regulations, facilitating faster and more efficient clinical trials.

    Essential insights emerge regarding the competitive advantages of conducting clinical research in Latin America, particularly in Colombia. Companies like bioaccess provide substantial cost savings and expedited regulatory approvals, while others such as Medpace and ICON plc emphasize the importance of comprehensive services that span the entire research lifecycle. The focus on quality assurance and regulatory support is critical, enhancing the integrity of studies and accelerating the pathway to market for groundbreaking therapies.

    As the clinical research landscape evolves, the importance of selecting the right support partner cannot be overstated. Organizations should leverage the strengths of these specialized companies to navigate the complexities of clinical trials effectively. By integrating innovative strategies and local expertise, clinical researchers can enhance their operational efficiency and contribute to advancing healthcare solutions that benefit patients worldwide. The call to action is clear: consider these leading support companies as essential allies in the pursuit of successful clinical outcomes.

    Frequently Asked Questions

    What is bioaccess and what services does it offer?

    bioaccess is a leading contract research organization (CRO) in Latin America that specializes in early-phase trial services for the Medtech, Biopharma, and Radiopharma sectors.

    What are the advantages of conducting clinical trials in Colombia through bioaccess?

    Advantages include substantial cost savings exceeding 30% compared to North America and Western Europe, a rapid regulatory review process for ethical approvals within 4-6 weeks, a high-quality healthcare system, and a diverse patient pool of over 50 million.

    What financial incentives are available for research and development in Colombia?

    R&D tax incentives in Colombia include 100% tax deductions and considerable government grants.

    How does Pharmalex support the pharmaceutical and biotechnology sectors?

    Pharmalex offers a comprehensive suite of compliance and quality assurance services throughout the product lifecycle, helping clients navigate regulatory complexities and ensuring adherence to regulations.

    What is Celerion’s focus in clinical research services?

    Celerion specializes in early-stage studies within the biopharmaceutical sector, offering services such as pharmacokinetics, pharmacodynamics, and bioanalytical support.

    How do bioaccess and Celerion collaborate to support clinical studies?

    bioaccess provides extensive CRO clinical study services in Colombia, including feasibility studies, site selection, compliance reviews, and project management, which facilitates faster patient enrollment and significant cost savings.

    What are the benefits of conducting clinical studies in Colombia compared to Western locations?

    Clinical studies in Colombia can result in patient enrollment being up to 50% quicker and cost savings of $25K per patient with FDA-ready data.

    List of Sources

    1. Pharmalex: Comprehensive Regulatory Affairs and Quality Assurance Services
      • pharmalex.com (https://pharmalex.com/pharmalex-insights/company-news)
      • pharmaceuticalmanufacturer.media (https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/latest-pharmaceutical-manufacturing-news/amerisourcebergen-completes-acquisition-of-pharmalex)
    2. PRA Health Sciences: Global Leader in Clinical Research and Regulatory Support
      • jaaqob.com (https://jaaqob.com/case_studies/tfs-healthscience)
      • drugpatentwatch.com (https://drugpatentwatch.com/blog/review-of-drugs-approved-via-the-505b2-pathway-uncovering-drug-development-trends-and-regulatory-requirements?srsltid=AfmBOopKyHcpZCZG0HsaT0y4RHhFVaqLvPPZupjSU-THL5U0zkUVK8ST)
      • couch.health (https://couch.health/case_studies/patient-recruitment-of-underserved-patients-in-the-us)
    3. QuintilesIMS: Integrated Services for Clinical Development and Regulatory Affairs
      • iqvia.com (https://iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025)
    4. Medpace: Full-Service Clinical Research Organization with Regulatory Expertise
      • cervicorninsights.wordpress.com (https://cervicorninsights.wordpress.com/2025/07/01/full-service-cro-market-3)
      • Contract Research Organization [CRO] Services Market, 2034 (https://fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864)
      • towardshealthcare.com (https://towardshealthcare.com/insights/healthcare-contract-research-organization-cro-market-sizing)
      • futuremarketinsights.com (https://futuremarketinsights.com/reports/healthcare-contract-research-organization-market)
      • globenewswire.com (https://globenewswire.com/news-release/2025/04/15/3061490/28124/en/Contract-Research-Organization-CRO-Market-Set-to-Grow-at-a-CAGR-of-8-1-Through-2034-as-Biopharma-Firms-Seek-Cost-Effective-Scalable-R-D-Solutions.html)

  • How to Hire a Local Representative for Medical Devices in Chile

    How to Hire a Local Representative for Medical Devices in Chile

    Introduction

    Navigating the complex landscape of hiring a local representative for medical devices in Chile demands a thorough understanding of both legal frameworks and industry-specific qualifications. This guide outlines the essential steps and considerations that foreign companies must take to ensure compliance and operational success in this growing market.

    As the demand for medical devices continues to rise, the challenge is in identifying the right representative-one who not only meets regulatory standards but also possesses the necessary industry knowledge and communication skills.

    What strategies can businesses implement to overcome these hurdles and secure a competent local representative?

    Before you hire Chile local representative devices, it is crucial to understand the nation’s labor laws and regulations. Key considerations include:

    • : Familiarize yourself with the Labor Code (Código del Trabajo), which governs employment relationships, including contracts, wages, and working conditions. Compliance with these regulations is essential to avoid legal complications.
    • : Foreign companies must appoint a legal agent who is either a Chilean citizen or a permanent resident. This representative uses hire chile local representative devices to manage legal matters and ensure compliance with regional laws, facilitating smoother operations in the Chilean market.
    • : Be aware of the tax implications associated with hiring in Chile, including income tax withholding and social security contributions. Understanding these obligations is vital for and avoiding penalties.
    • : All employees must have a written employment contract that clearly outlines their rights and obligations. These contracts must comply with local laws and include necessary clauses regarding termination, benefits, and working hours.
    • : Organizations with 25 or more employees must ensure that at least 85% of their workforce consists of Chilean citizens, a significant legal requirement for foreign entities operating in Chile.
    • Non-Discrimination: The Labor Code prohibits discrimination based on various personal characteristics during the hiring process, ensuring fair hiring practices.
    • Digital Disconnection: Employers are required to guarantee the right to digital disconnection for remote employees, reflecting the increasing prevalence of remote work in Chile.
    • : As of January 2026, the is set at CLP 213,354, affecting payroll and regulations.

    By thoroughly understanding these legal requirements, foreign companies can navigate the hiring process effectively, minimizing risks and ensuring adherence to Chilean labor laws.

    The central node represents the overall legal framework, while each branch highlights a specific legal consideration. Follow the branches to explore each topic and its importance in the hiring process.

    Identify Requirements for Hiring a Local Representative in Medical Devices

    When you hire Chile local representative devices for , it’s crucial to consider several that will ensure your success in this competitive market.

    • Industry Knowledge: Look for a representative who has a deep understanding of the , including the regulatory landscape and market dynamics unique to Chile. This knowledge is foundational for navigating the complexities of the industry.
    • Regulatory Expertise: Candidates must demonstrate proven experience with the Chilean , particularly with the (ISP) and other relevant authorities. This expertise is vital, especially given the recent for , including immunohematological reagents.
    • : Effective communication is essential for interacting with regulatory bodies, healthcare professionals, and stakeholders. Ensure that your representative is fluent in both Spanish and English to facilitate clear and effective dialogue.
    • Networking Ability: A representative with , including potential clients and partners in the healthcare sector, thereby enhancing your market access.
    • : Prior experience in medical device sales or regulatory affairs is highly advantageous. This background equips the individual with the necessary skills to advocate effectively for your products.

    By clearly defining these requirements, you streamline the and position yourself to select an individual who will effectively support your business objectives in the evolving Chilean market. What challenges do you face in finding the right representative?

    The center represents the main hiring requirements, and each branch shows a specific qualification needed. Follow the branches to understand what to look for in a representative.

    Explore Hiring Models: Direct Employment vs. Employer of Record

    When considering how to hire a , it’s crucial to understand the two primary models available:

    • Direct Employment: This model involves hiring the representative as a . It allows for enhanced oversight of the representative’s actions and ensures alignment with your organization’s objectives. However, it requires strict adherence to , including payroll management and benefits administration.

      • Pros: Direct oversight, alignment with organizational culture, and potential for .
      • Cons: Higher and potential legal complexities.

    • : An EOR acts as the official employer for your representative, managing all regulatory, payroll, and HR responsibilities. This model is particularly advantageous for companies aiming to enter the market quickly without the need to establish a .

      • Pros: , reduced , and .
      • Cons: Less direct control over the agent’s activities and potential higher costs.

    Evaluate these models based on your organization’s resources, timeline, and strategic goals to determine the best fit for your needs.

    The central node represents the main topic of hiring models. Each branch leads to a specific model, with further branches detailing the advantages and disadvantages. This layout helps you quickly see the key points for each option.

    Ensure Compliance and Manage Your Local Representative Effectively

    To ensure compliance and effective management of your , consider these :

    1. Regular Training: Ongoing training is crucial for keeping your representative updated on , compliance requirements, and company policies. This ensures they remain informed and capable of navigating the local landscape effectively.
    2. : Clearly define the roles, responsibilities, and performance metrics of the individual. This alignment with your business objectives is essential for achieving desired outcomes and maintaining accountability.
    3. Establish Communication Channels: Open lines of communication are vital for facilitating feedback and addressing concerns. This support fosters a positive working relationship and enables the individual to perform effectively.
    4. : Routine evaluations of the agent’s activities are essential to guarantee conformity with regional regulations and company policies. This may involve conducting audits and performance evaluations to maintain high standards.
    5. : Promote teamwork between your internal groups and the regional contact. This enhances knowledge sharing and operational efficiency, ultimately benefiting your business.

    Applying these strategies will assist you in efficiently overseeing your hire chile local representative devices, ensuring adherence and maximizing their contribution to your success in Chile. With the projected to expand at a compound annual growth rate of 15% until 2027, is essential. Additionally, leveraging comprehensive – including feasibility studies, site selection, compliance reviews, trial setup, import permits, project management, and reporting – will further enhance your operational success.

    Each box represents a crucial step in managing your local representative. Follow the arrows to see how each practice builds on the previous one, leading to effective compliance and management.

    Conclusion

    Hiring a local representative for medical devices in Chile is not just a task; it’s a strategic move that demands careful attention to legal, regulatory, and operational factors. Understanding the nuances of Chile’s labor laws, including compliance with the Labor Code and tax obligations, is crucial for navigating this landscape effectively. Moreover, defining the qualifications and skills necessary for representatives – such as industry knowledge and regulatory expertise – ensures that businesses can advocate for their products in a competitive market.

    Selecting the right hiring model is paramount. Whether opting for direct employment or utilizing an Employer of Record (EOR), aligning with organizational goals can streamline operations and enhance effectiveness. Additionally, best practices for managing local representatives – like regular training, setting clear expectations, and fostering effective communication – are vital for maintaining compliance and nurturing a productive working relationship.

    As the medical device market in Chile continues to expand, taking proactive steps in hiring and managing local representatives will be essential for success. Companies must stay informed about evolving regulations and invest in the right talent to navigate this dynamic environment. By doing so, they can seize the opportunities presented in Chile’s growing medical device sector, ensuring sustainable growth for their business.

    Frequently Asked Questions

    What is the Labor Code in Chile?

    The Labor Code (Código del Trabajo) governs employment relationships in Chile, including aspects such as contracts, wages, and working conditions. Compliance with this code is essential for avoiding legal complications.

    What are the legal representation requirements for foreign companies hiring in Chile?

    Foreign companies must appoint a legal agent who is either a Chilean citizen or a permanent resident. This representative manages legal matters and ensures compliance with local laws.

    What tax obligations should companies be aware of when hiring in Chile?

    Companies must understand tax implications such as income tax withholding and social security contributions. Awareness of these obligations is vital for maintaining compliance and avoiding penalties.

    Are employment contracts required in Chile?

    Yes, all employees must have a written employment contract that outlines their rights and obligations. These contracts must comply with local laws and include necessary clauses regarding termination, benefits, and working hours.

    What are the hiring quotas for foreign entities in Chile?

    Organizations with 25 or more employees must ensure that at least 85% of their workforce consists of Chilean citizens, which is a significant legal requirement for foreign entities operating in the country.

    Is discrimination allowed in the hiring process in Chile?

    No, the Labor Code prohibits discrimination based on various personal characteristics during the hiring process, ensuring fair hiring practices.

    What is the right to digital disconnection for remote employees in Chile?

    Employers are required to guarantee the right to digital disconnection for remote employees, reflecting the growing prevalence of remote work in Chile.

    What is the legal gratification cap in Chile as of January 2026?

    The legal gratification cap is set at CLP 213,354, which will affect payroll and regulations starting in January 2026.

    List of Sources

    1. Understand the Legal Framework for Hiring in Chile
      • kpmg.com (https://kpmg.com/xx/en/our-insights/gms-flash-alert/2026/flash-alert-2026-032.html)
      • leglobal.law (https://leglobal.law/countries/chile/employment-law/employment-law-overview-chile/01-hiring-practices)
      • cxcglobal.com (https://cxcglobal.com/global-hiring-guide/chile/employment-contracts-in-chile)
      • globallegalinsights.com (https://globallegalinsights.com/practice-areas/employment-and-labour-laws-and-regulations/chile)
    2. Identify Requirements for Hiring a Local Representative in Medical Devices
      • regdesk.co (https://regdesk.co/regulations-library/chile)
      • omcmedical.com (https://omcmedical.com/chile-medical-device-registration)
      • gpcgateway.com (https://gpcgateway.com/regulatory-regions/chile/news-detail/chile-strengthens-medical-device-regulations-MTgzOQ==)
      • lamaaccess.com (https://lamaaccess.com/quick-guide-to-medical-device-registration-and-market-access-in-chile)
    3. Explore Hiring Models: Direct Employment vs. Employer of Record
      • safeguardglobal.com (https://safeguardglobal.com/country/chile/eor)
      • omnipresent.com (https://omnipresent.com/articles/employer-of-record-pros-and-cons)
      • hroptions.com (https://hroptions.com/employer-of-record-vs-direct-hiring)
      • asanify.com (https://asanify.com/global-employer-of-record/chile/how-to-hire)
      • oysterhr.com (https://oysterhr.com/library/employers-of-record-in-chile)
    4. Ensure Compliance and Manage Your Local Representative Effectively
      • bioaccessla.com (https://bioaccessla.com/blog/medical-device-trial-strategies-in-chile-optimize-success-and-compliance)
      • compliancebridge.com (https://compliancebridge.com/4-quote-that-underscore-importance-of)
      • meddeviceonline.com (https://meddeviceonline.com/doc/medtech-in-chile-currently-latin-america-s-easiest-market-but-for-how-long-0001)

  • Master Clinical Trial Management in Chile: Best Practices for Success

    Master Clinical Trial Management in Chile: Best Practices for Success

    Introduction

    Navigating the complexities of clinical trial management in Chile can be daunting, yet it offers significant opportunities for those who master it. With a regulatory landscape that promises expedited approval timelines and a growing pool of potential participants, understanding the intricacies of compliance and recruitment strategies is crucial for success.

    Let’s explore how sponsors can effectively leverage local insights and technology to ensure their studies meet regulatory standards and resonate with diverse patient populations. By embracing local insights and technological advancements, sponsors can not only meet regulatory standards but also connect meaningfully with diverse patient populations.

    Understand the Regulatory Landscape for Clinical Trials in Chile

    Navigating the regulatory landscape for clinical trial management in Chile can be a daunting task for sponsors, yet understanding the approval process is crucial for success in clinical trial management Chile. Chile’s regulatory structure for medical studies is primarily overseen by the Instituto de Salud Pública (ISP), which manages the approval process for all research involving human participants. To kick off a clinical study, sponsors need to submit a Clinical Trial Application (CTA), which should detail study protocols, informed consent forms, and the qualifications of investigators. The typical approval timeline in Chile is around 30 days, considerably quicker than numerous other areas, making it an appealing choice for first-in-human studies.

    Key compliance requirements include adherence to International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, which ensure the ethical and scientific quality of studies. Furthermore, all studies must obtain ethical approval from a regional ethics committee, which assesses the study’s design and its impact on participant safety.

    Compliance Requirements and Submission Pathways

    • Clinical Trial Application (CTA): Must include detailed study protocols, informed consent forms, and qualifications of investigators.
    • ICH-GCP Standards: Compliance with these standards is mandatory for all clinical trials.
    • Ethical Approval: Required from a local ethics committee to assess participant safety and study design.

    Understanding these compliance nuances is essential for sponsors to navigate the approval process smoothly and avoid delays that could jeopardize their timelines and funding. By leveraging insights from bioaccess®’s Global Trial Accelerators™, sponsors can remain updated on regulatory changes and market access strategies, which is crucial for effective clinical trial management in Chile and further improving their capability to conduct successful studies. Embracing these compliance insights not only mitigates risks but also positions sponsors for success in the competitive landscape of clinical trial management in Chile.

    This flowchart outlines the steps sponsors need to take to navigate the regulatory landscape for clinical trials in Chile. Start at the top and follow the arrows to see what actions are required at each stage, from submitting applications to obtaining necessary approvals.

    Implement Effective Patient Recruitment Strategies in Chile

    Recruiting participants for clinical trial management in Chile presents unique challenges that demand a strategic and community-focused approach. Partnering with local healthcare providers is essential for pinpointing potential participants. This collaboration can be bolstered through outreach programs that inform healthcare professionals about the study’s objectives and eligibility criteria, ensuring a clear understanding of the research’s importance.

    In fact, studies show that digital platforms can boost recruitment by up to 30%, making them indispensable in reaching diverse patient populations, particularly in urban areas where access to information is more widespread. Engaging with patient advocacy groups can further enhance trust and promote involvement, fostering a supportive atmosphere for potential study candidates.

    Understanding cultural factors is critical when crafting effective recruitment strategies. Tailoring messaging to resonate with local communities can significantly improve engagement and retention rates. For instance, emphasizing the possible advantages of participation-such as access to innovative treatments and the chance to contribute to medical advancements-can encourage individuals to enroll in studies. By embracing these tailored strategies, sponsors can not only enhance recruitment success in clinical trial management Chile but also ensure that their studies reflect the diverse needs of the Chilean population.

    This mindmap starts with the main idea at the center and branches out to show different strategies for recruiting patients in clinical trials. Each branch represents a key area of focus, and the sub-branches provide more details on specific actions or considerations. Follow the branches to see how these strategies connect and support each other.

    Leverage Technology for Streamlined Clinical Trial Management

    In the rapidly evolving landscape of clinical research, integrating technology is no longer optional; it’s essential for success. Integrating technology into the management of research studies significantly improves efficiency and ensures data integrity, particularly in first-in-human studies conducted in Latin America. Utilizing Electronic Data Capture (EDC) systems facilitates real-time data collection and monitoring, significantly reducing the risk of errors associated with manual data entry. Prominent platforms like Medidata Rave and Veeva Vault CDMS are widely acknowledged for their strong capabilities in managing research data, ensuring adherence to ICH-GCP standards, and facilitating submissions to regulatory bodies such as:

    • ANVISA in Brazil
    • INVIMA in Colombia
    • COFEPRIS in Mexico

    Additionally, project management software enhances task coordination, timelines, and team communication. This ensures all stakeholders remain aligned throughout the study process. Tools such as Asana or Trello are especially effective for monitoring progress and managing deadlines, which is crucial in the fast-paced setting of early-stage studies.

    Moreover, integrating telemedicine solutions enhances patient engagement and retention by enabling remote consultations and follow-ups. This method is particularly valuable in first-in-human trials, prioritizing patient safety and convenience. By utilizing these technologies, sponsors can enhance operational efficiency, lower expenses, and expedite the process to regulatory approval, ultimately reaching their milestones more effectively in the dynamic landscape of Latin American research.

    With bioaccess®, the advantages are even more pronounced, as the platform facilitates ethics approvals in just 4-8 weeks, significantly faster than the 6+ months typically required in the US and EU. This speed not only allows for quicker access to clinical data but also translates into substantial cost savings-up to $25K per patient-through pre-negotiated site contracts. By allocating these savings into R&D or upcoming funding milestones, sponsors can extend their runway and improve their overall study strategy. It is also crucial to consider potential challenges in EDC implementation, such as ensuring proper training for site staff to uphold data integrity and compliance with regional regulations. Without embracing these advancements, sponsors risk falling behind in the competitive field of clinical research.

    This mindmap illustrates how various technologies contribute to effective clinical trial management. Start at the center with the main theme, then explore each branch to see how different tools and strategies enhance efficiency, data integrity, and patient engagement.

    Foster Collaboration with Local Stakeholders for Success

    In the competitive landscape of clinical trial management in Chile, establishing strong connections with local stakeholders is not just beneficial; it’s essential for success. Engaging with oversight authorities, particularly the Instituto de Salud Pública (ISP), is crucial for clarifying expectations and expediting the approval process. The ISP manages the authorization of research projects, ensuring adherence to ICH-GCP standards. Grasping the ISP’s role in the approval process can greatly boost study execution efficiency. They ensure that all research complies with necessary regulatory requirements.

    Collaboration with regional investigators who possess in-depth knowledge of the patient population and clinical landscape significantly enhances recruitment efforts. These investigators can offer valuable insights into patient needs and preferences, informing culturally appropriate study protocols and improving participant retention rates. For instance, Chile currently has 20.8 registered ongoing studies per million inhabitants, highlighting the competitive environment for patient recruitment.

    Getting involved in local conferences and networking events is a smart way to connect with potential partners and stakeholders. By engaging with the clinical research community in Chile, sponsors can foster a collaborative environment that supports clinical trial management in Chile, thereby accelerating the development of innovative therapies. As one of our clients pointed out, ‘Collaborating with bioaccess® enabled us to navigate the compliance landscape effectively, resulting in a successful study launch in record time.’

    Moreover, incorporating Equality, Diversity, and Inclusion (EDI) principles into trial design is becoming increasingly essential, as oversight bodies anticipate proof of authentic dedication to these principles. To effectively engage with local stakeholders, consider the following actionable steps:

    1. Schedule regular meetings with the ISP to discuss regulatory updates and expectations.
    2. Engage with regional investigators early in the study design process to ensure cultural relevance.
    3. Attend local conferences to network with potential partners and stay informed about industry trends.
    4. Develop EDI-focused recruitment strategies to enhance diversity in participation of clinical studies.
    5. Create a feedback loop with stakeholders to continuously improve engagement strategies.

    This proactive approach to stakeholder engagement is vital for navigating the complexities of clinical trial management in Chile. Without collaboration, researchers risk delays and inefficiencies that can derail their studies. By prioritizing stakeholder engagement, researchers can not only enhance their study outcomes but also contribute to the advancement of clinical research in the region.

    Each box represents a step you can take to improve collaboration with local stakeholders. Follow the arrows to see the recommended order of actions for successful clinical trial management.

    Conclusion

    Mastering clinical trial management in Chile is not just about understanding regulations; it’s about overcoming significant challenges that can hinder success. Focusing on these areas empowers sponsors to conquer the complexities of clinical trials with confidence and efficiency. The insights provided throughout this article highlight the importance of compliance with local regulations, the necessity of community engagement for recruitment, and the pivotal role technology plays in optimizing trial processes.

    Key points discussed include:

    1. The need for a thorough grasp of the Clinical Trial Application (CTA) process overseen by the Instituto de Salud Pública (ISP).
    2. The significance of building partnerships with local healthcare providers to enhance recruitment.
    3. The advantages of employing advanced technologies such as Electronic Data Capture (EDC) systems.

    Each of these elements contributes to reducing timelines, ensuring data integrity, and ultimately leading to successful trial outcomes.

    In conclusion, embracing these best practices not only positions sponsors for success in the competitive landscape of clinical trial management in Chile but also reinforces the significance of strategic planning and collaboration. As the demand for innovative therapies continues to rise, leveraging Chile’s regulatory advantages and fostering local partnerships will be essential for driving forward the future of clinical research in Latin America. Acting on these insights today will not only enhance operational efficiencies but also shape the future of clinical research in Latin America.

    Frequently Asked Questions

    What is the primary regulatory authority overseeing clinical trials in Chile?

    The primary regulatory authority overseeing clinical trials in Chile is the Instituto de Salud Pública (ISP), which manages the approval process for all research involving human participants.

    What is required to initiate a clinical study in Chile?

    To initiate a clinical study in Chile, sponsors must submit a Clinical Trial Application (CTA), which should include detailed study protocols, informed consent forms, and the qualifications of investigators.

    What is the typical approval timeline for clinical trials in Chile?

    The typical approval timeline for clinical trials in Chile is around 30 days, which is considerably quicker than many other regions, making it an attractive option for first-in-human studies.

    What compliance standards must be followed for clinical trials in Chile?

    All clinical trials in Chile must comply with the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, which ensure the ethical and scientific quality of studies.

    Is ethical approval necessary for clinical trials in Chile?

    Yes, ethical approval is required from a local ethics committee, which assesses the study’s design and its impact on participant safety.

    How can sponsors stay updated on regulatory changes in Chile?

    Sponsors can leverage insights from bioaccess®’s Global Trial Accelerators™ to remain updated on regulatory changes and market access strategies, which is crucial for effective clinical trial management in Chile.

    Why is it important for sponsors to understand compliance requirements in Chile?

    Understanding compliance requirements is essential for sponsors to navigate the approval process smoothly and avoid delays that could jeopardize their timelines and funding, ultimately positioning them for success in the competitive landscape of clinical trial management in Chile.

    List of Sources

    1. Understand the Regulatory Landscape for Clinical Trials in Chile
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trial-supply-logistics-market/chile)
      • reedintelligence.com (https://reedintelligence.com/insights/clinical-trial-management-system-market/chile)
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
    2. Implement Effective Patient Recruitment Strategies in Chile
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • bioaccessla.com (https://bioaccessla.com/blog/4-best-practices-for-medtech-clinical-trials-in-chile)
      • How to Conduct First-in-Human Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/how-to-conduct-first-in-human-trials-in-chile-a-step-by-step-guide)
      • Navigate Biopharma Clinical Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/navigate-biopharma-clinical-trials-in-chile-a-step-by-step-guide)
    3. Leverage Technology for Streamlined Clinical Trial Management
      • careset.com (https://careset.com/10-benefits-of-edc-electronic-data-capture-for-clinical-trials)
      • Electronic Data Capture Systems for Clinical Trials and Research (https://egnyte.com/guides/life-sciences/electronic-data-capture)
      • 8 key benefits of electronic data capture for clinical trials | Viedoc (https://viedoc.com/blog/key-benefits-electronic-data-capture-clinical-trials)
      • 20 hospital execs’ most thought-provoking quotes on health IT in 2021 – Becker’s Hospital Review | Healthcare News & Analysis (https://beckershospitalreview.com/healthcare-information-technology/innovation/20-hospital-execs-most-thought-provoking-quotes-on-health-it-in-2021)
      • minervaresearchsolutions.com (https://minervaresearchsolutions.com/electronic-data-capture-system-in-clinical-trials)
    4. Foster Collaboration with Local Stakeholders for Success
      • bioaccessla.com (https://bioaccessla.com/blog/best-practices-for-selecting-investigator-sites-in-chile-for-clinical-trials)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC12670741)
      • psychologytoday.com (https://psychologytoday.com/us/blog/here-there-and-everywhere/201205/25-quotes-on-collaboration)
      • nclusiv.co.uk (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)

  • Master Affordable Clinical Trials in Chile: A Step-by-Step Approach

    Master Affordable Clinical Trials in Chile: A Step-by-Step Approach

    Introduction

    While Chile offers a great chance for MedTech and Biopharma companies to innovate while keeping costs in check, the path to success is fraught with challenges that require strategic navigation.

    With a regulatory framework that supports swift approvals and a diverse patient population, Chile stands out as a strategic location for first-in-human studies.

    Yet, navigating local regulations can be daunting for sponsors, often leading to delays and increased costs, especially when it comes to engaging patients effectively.

    What strategies can sponsors adopt to truly harness Chile’s advantages for successful and cost-effective clinical trials?

    Understand Early Phase Clinical Trials in Chile

    Initial phase clinical evaluations, particularly first-in-human (FIH) studies, are pivotal in the drug development process, shaping the future of innovative therapies. In this country, these studies are backed by a strong regulatory framework supervised by the Instituto de Salud Pública (ISP), which guarantees adherence to ICH-GCP standards. The approval process typically lasts between 30 to 60 days, with the ISP assessing applications within 30 business days. Conducting an affordable clinical trial in Chile offers a cost advantage of up to 40% compared to the U.S., positioning it as a strategic choice for MedTech and Biopharma startups.

    Essential elements to consider are:

    • Regulatory Framework: The ISP governs clinical trials, ensuring adherence to national and international guidelines. Familiarity with these regulations is essential for successful execution of the study.
    • Cost Efficiency: The reduced operational expenses in the region enable sponsors to allocate resources more effectively, which is essential for startups functioning with constrained budgets. This cost advantage can significantly enhance the financial viability of affordable clinical trial Chile during early phase studies.
    • Diverse Patient Population: The varied demographics of the country enhance recruitment potential, offering access to a broad spectrum of participants for research studies. This diversity accelerates enrollment and significantly enhances the representativeness of study results, a critical factor in clinical research.

    By comprehending these components and utilizing insights from bioaccess®’s Global Trial Accelerators™, sponsors can enhance their readiness for the challenges and opportunities that early phase studies present in the region, ultimately driving their research towards success.

    This mindmap starts with the central theme of early phase clinical trials in Chile. Each branch represents a crucial aspect of the trials, showing how they relate to one another and contribute to the overall success of drug development in the region.

    To successfully conduct clinical studies in Chile, sponsors must adeptly navigate a complex regulatory landscape established by the Instituto de Salud Pública (ISP) and the Agencia Nacional de Medicamentos (ANAMED). Here’s a step-by-step approach:

    1. Prepare Documentation: Gather all essential documents, including the research protocol, informed consent forms, and investigator brochures. Ensure that these documents adhere to ICH-GCP standards, which are vital for upholding the integrity and quality of the study.
    2. Submit Application: Submit your clinical study application to the ISP, including all compiled documents and any additional information requested by the regulatory body. This submission is crucial for kickstarting the approval process.
    3. Approval Timeline: The average duration for approval is approximately 30 business days, significantly faster than many other regions. The ISP has streamlined the research approval process, minimizing bureaucratic delays by over 30%. This represents a major advantage for conducting studies in Chile, enabling sponsors to commence trials more swiftly, particularly advantageous for First-in-Human (FIH) evaluations.
    4. Ethics Committee Review: Concurrently, submit your research for evaluation by an accredited ethics committee (EC). This step is vital for guaranteeing participant safety and ethical adherence, as only accredited ECs can approve research protocols. Compliance with the Declaration of Helsinki and local ethical standards is mandatory.
    5. Post-Approval Compliance: Once approved, you’ll need to keep up with regular reporting to the ISP and follow any conditions laid out during the approval process. Additionally, after receiving ISP approval, it’s essential to notify ANAMED to ensure all regulatory steps are completed.
    6. Develop Recruitment Strategy: A robust recruitment plan is essential for enrolling participants in research initiatives. Understanding the socio-political context in the region, including potential barriers to patient access, can enhance recruitment efforts and ensure a diverse participant pool. Leveraging bioaccess®’s expertise in early feasibility studies can further streamline this process, ensuring that sponsors can effectively engage with potential participants.

    By adhering to these procedures and leveraging bioaccess®’s offerings, sponsors can optimize their regulatory submissions and improve the chances of a successful study launch in the region, positioning themselves for success in the dynamic Latin American market.

    This flowchart outlines the steps needed to navigate the regulatory landscape for clinical trials in Chile. Each box represents a key step in the process, and the arrows show how to move from one step to the next. Follow the flow to ensure you complete all necessary actions for a successful study launch.

    Implement Strategies for Successful Trial Execution

    Navigating the complex regulatory landscape in Chile can be daunting for sponsors, but adopting an affordable clinical trial Chile strategy can pave the way for successful medical research implementation. Here are key strategies to consider:

    1. Site Selection: Prioritize research locations with a proven track record in early phase studies. Assess their experience, infrastructure, and patient access to ensure they can meet the specific requirements of your study. Considering that over 96% of clinical studies in Chile are financed by external pharmaceutical companies, selecting sites with established relationships can enhance recruitment and retention for affordable clinical trial Chile. Utilizing bioaccess®’s pre-negotiated site agreements can result in substantial cost reductions of $25K per patient, improving the overall feasibility of your study.
    2. Risk-Based Monitoring: Implement a strategy focused on high-risk areas of the study by allocating resources effectively. This approach allows for early identification of potential issues, facilitating timely interventions and ensuring compliance with ICH-GCP standards. Reports suggest that effective risk management can greatly enhance research outcomes by addressing challenges proactively.
    3. Training and Support: Providing ongoing support during the study not only boosts data quality but also keeps participants safe, which is essential for preserving the integrity of the research and fulfilling regulatory expectations. Bioaccess® offers tailored training programs that align with local regulations, ensuring that your team is well-prepared.
    4. Data Management: Utilize robust data management systems to ensure accurate and timely data collection. This is crucial for preserving study integrity and enabling regulatory submissions, especially considering the average response time of 15 days from the Chilean Institute of Public Health for registration data. With bioaccess®, you can benefit from advanced data management solutions that streamline the process and improve efficiency.
    5. Communication: Establish clear communication channels among all stakeholders, including sponsors, investigators, and regulatory bodies. Regular updates and feedback loops can help address challenges promptly, ensuring that all parties are aligned and informed throughout the research process. Bioaccess® facilitates effective communication through its Global Trial Accelerators™, providing essential insights and market access strategies tailored for MedTech and Biopharma innovators in Latin America.

    By embracing these strategies, sponsors not only enhance their study outcomes but also contribute to the advancement of affordable clinical trial Chile in healthcare.

    Each box represents a key strategy for executing clinical trials successfully. Follow the arrows to see how each strategy builds on the previous one, guiding you through the process of enhancing study outcomes.

    Enhance Patient Recruitment and Retention Strategies

    Despite the critical importance of patient enrollment and retention, many studies in Chile struggle to engage participants effectively in affordable clinical trial settings. Here are targeted strategies to enhance these processes:

    1. Community Engagement: Actively engage with local communities to raise awareness about clinical trials. Utilize local media, community events, and partnerships with healthcare providers to effectively reach potential participants. This approach fosters trust and encourages participation, as evidenced by the strong doctor-patient relationships prevalent in the region.
    2. Digital Outreach: Leverage digital platforms for recruitment campaigns. Social media, online forums, and patient registries can efficiently identify and engage eligible candidates. Have you thought about using direct mail campaigns and targeted Facebook advertisements? One report indicates over 2.5 million impressions from Facebook ads alone, resulting in increased inquiries.
    3. Incentives: Have you thought about offering incentives for participation, like travel reimbursements or health screenings? These incentives can motivate individuals to enroll and remain committed to the study, addressing potential barriers to participation.
    4. Patient-Centric Approach: Design studies with the patient experience in mind. Streamline participation processes, offer clear information about the study, and ensure that participants feel appreciated and supported throughout their involvement. This approach can significantly enhance retention rates.
    5. Retention Strategies: Implement proactive retention strategies, such as regular follow-ups and personalized communication. Address participant concerns promptly and provide updates on study progress to keep them engaged. Community Advisory Groups (CAGs) can play a vital role in maintaining participant engagement by fostering a sense of community and support.

    Improving these strategies is not just beneficial; it is essential for the integrity and success of affordable clinical trial Chile.

    This mindmap starts with the main goal of improving patient recruitment and retention in clinical trials. Each branch represents a different strategy, and the sub-branches provide more details on how to implement these strategies. Follow the branches to see how each approach contributes to the overall goal.

    Conclusion

    Conducting affordable clinical trials in Chile presents a unique opportunity for MedTech and Biopharma companies willing to tackle the complexities of early phase studies. Chile’s robust regulatory framework, cost efficiency, and diverse patient population provide strategic advantages that foster innovative research. Leveraging these factors is essential for achieving successful outcomes in clinical trials.

    Key insights from this guide highlight the importance of:

    1. Navigating regulatory requirements effectively
    2. Implementing robust recruitment strategies
    3. Ensuring compliance with ICH-GCP standards

    Sponsors must adopt a structured approach to documentation, approval processes, and participant engagement to streamline operations and mitigate risks. Furthermore, embracing community engagement and digital outreach can improve patient recruitment and retention, which are crucial for the integrity of clinical trials.

    In conclusion, the landscape for early phase clinical trials in Chile is not only favorable but also ripe with potential for those willing to adopt a strategic approach. By taking advantage of the cost-effective solutions and regulatory efficiencies available, sponsors can position themselves for success in the competitive field of clinical research. To thrive in this competitive landscape, stakeholders must act decisively, embracing the opportunities that lie ahead.

    Frequently Asked Questions

    What are early phase clinical trials, specifically first-in-human (FIH) studies?

    Early phase clinical trials, particularly FIH studies, are critical in the drug development process as they evaluate the safety and efficacy of new therapies in humans for the first time.

    What regulatory body oversees clinical trials in Chile?

    The Instituto de Salud Pública (ISP) is the regulatory authority that governs clinical trials in Chile, ensuring compliance with national and international standards, including ICH-GCP guidelines.

    How long does the approval process for clinical trials take in Chile?

    The approval process typically lasts between 30 to 60 days, with the ISP assessing applications within 30 business days.

    What are the cost advantages of conducting clinical trials in Chile compared to the U.S.?

    Conducting clinical trials in Chile can offer a cost advantage of up to 40% compared to the U.S., making it a strategic choice for MedTech and Biopharma startups.

    Why is the regulatory framework important for clinical trials in Chile?

    The regulatory framework established by the ISP is essential for ensuring that clinical trials adhere to both national and international guidelines, which is crucial for the successful execution of studies.

    How does the diverse patient population in Chile benefit clinical trials?

    The varied demographics in Chile enhance recruitment potential, allowing access to a broad spectrum of participants. This diversity accelerates enrollment and improves the representativeness of study results, which is vital for clinical research.

    How can sponsors prepare for early phase studies in Chile?

    Sponsors can enhance their readiness for early phase studies by understanding the regulatory framework, leveraging cost efficiency, and utilizing insights from bioaccess®’s Global Trial Accelerators™ to navigate challenges and opportunities in the region.

    List of Sources

    1. Understand Early Phase Clinical Trials in Chile
      • scielo.cl (https://scielo.cl/article_plus.php?pid=S0034-98872021000100110&tlng=en&lng=es)
      • cms.bioaccessla.com (https://cms.bioaccessla.com/blog/master-early-phase-clinical-trials-in-chile-key-strategies-and-insights)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOorZfdDWgLFN4scg4mpP4PN4GvW5AlH4oBlN3ZPu_u7GVhAZzokh)
    2. Navigate Regulatory Requirements for Clinical Trials
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOoqAaIyhPOudE-3CnJ-2rG8iEkg32x2e8C9jKw8O98pAIF_Ci2N5)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • bioaccessla.com (https://bioaccessla.com/blog/master-fda-accepted-clinical-trials-in-chile-a-step-by-step-tutorial)
      • Clinical Trials in Latin America (https://languageconnections.com/clinical-trials-in-latin-america)
      • How to Conduct First-in-Human Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/how-to-conduct-first-in-human-trials-in-chile-a-step-by-step-guide)
    3. Implement Strategies for Successful Trial Execution
      • scielo.cl (https://scielo.cl/article_plus.php?pid=S0034-98872021000100110&tlng=en&lng=es)
      • bioaccessla.com (https://bioaccessla.com/blog/best-practices-for-selecting-investigator-sites-in-chile-for-clinical-trials)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOoo2lZFnkVetcBVZ7wGD75q2hgzL9HxCsd3fRjZ4_UyDRXJVOENx)
    4. Enhance Patient Recruitment and Retention Strategies
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOopgWM_mePVImKyY_G0yLadVejeP-2EpQOKrCVwDv9_Hse-lRqX-)
      • jpsmjournal.com (https://jpsmjournal.com/article/S0885-3924(23)00398-6/fulltext)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC12444702)

  • Optimize Clinical Trial Costs in Chile: Best Practices for Success

    Optimize Clinical Trial Costs in Chile: Best Practices for Success

    Introduction

    While Chile offers enticing financial advantages for clinical research, the path to successful study execution is fraught with challenges that demand strategic navigation. Chile has emerged as a beacon for clinical research, particularly for first-in-human studies, with clinical trial costs being 30% to 75% lower than in the U.S. and Europe. This financial landscape allows startups to optimize their budgets and resources effectively.

    Despite the financial advantages, many companies struggle to effectively manage the complexities of clinical trials in Chile. To truly harness the potential of Chile’s clinical research landscape, companies must not only recognize these challenges but also develop robust strategies to overcome them.

    Understand the Financial Landscape of Clinical Trials in Chile

    Chile stands out as a prime destination for clinical research, particularly for first-in-human studies, because the clinical trial cost in Chile is significantly lower compared to the U.S. and Europe. The clinical trial cost in Chile can be conducted at levels that are roughly 30% to 75% lower than in developed markets. Several key factors contribute to this cost efficiency:

    • Lower Site Costs: Clinical research sites in Chile typically incur reduced overhead, resulting in lower fees for sponsors. This is particularly advantageous for startups looking to maximize their budgets.
    • Government Incentives: The Chilean government actively supports clinical research through various incentives, including tax breaks and grants for innovative studies, which can further reduce overall study costs.
    • Access to Funding: Startups can leverage regional venture capital and government funding programs specifically designed to support healthcare innovations, enhancing their financial viability.
    • Regulatory Framework: Navigating the regulatory landscape can be daunting for many sponsors, often leading to delays and increased costs. Compliance with regional regulatory authorities such as the Instituto de Salud Pública (ISP) and adherence to ICH-GCP standards are essential for study approval. Understanding the submission pathways and approval timelines can significantly expedite the process.

    When sponsors grasp these financial dynamics and regulatory requirements, they can really optimize their budgets and allocate resources effectively, ensuring they hit their first-in-human milestones without draining their capital reserves. This strategic approach not only facilitates faster study execution but also aligns with the regulatory frameworks established by local authorities, ensuring compliance and expediting the approval process. Have you considered how per-patient expenditures in LATAM, ranging from $15,000 to $35,000, compare to the $40,000 to $75,000 in the US/EU? This stark difference underscores the financial advantages of conducting studies, particularly considering the clinical trial cost in Chile. With insights from bioaccess®, MedTech startups can navigate these financial landscapes more effectively, ensuring successful study outcomes.

    This mindmap illustrates the key factors that make Chile an attractive location for clinical trials. Each branch represents a different aspect of the financial landscape, showing how they contribute to lower costs and better funding opportunities for clinical research.

    Implement Strategic Budgeting and Cost Management Techniques

    To thrive in the competitive landscape of clinical trials in Chile, startups must master budgeting and cost management techniques:

    • Detailed Budget Forecasting: Develop a comprehensive budget that encompasses all potential costs, including site fees, patient recruitment, and regulatory submissions. Historical data from previous studies can provide valuable insights for more accurate estimates. For instance, utilizing historical data can assist in forecasting expenses related to site payments and patient recruitment, which are essential for sustaining financial oversight. In Latin America, understanding the clinical trial cost in Chile, which can be 30% lower than in the US/EU, is crucial.
    • Regular Budget Reviews: Have you considered implementing periodic budget reviews to identify variances and adjust forecasts accordingly? This proactive strategy aids in managing unexpected expenses and maintaining financial control. As operational burdens rise in 2024, startups may struggle to keep budgets on track without regular reviews, especially in a region where regulatory timelines can be significantly shorter.
    • Negotiate Contracts: Engage in negotiations with vendors and service providers to secure favorable terms. The competitive landscape in Chile can be leveraged to obtain better pricing, which is crucial for startups managing the clinical trial cost in Chile on tight budgets. Comprehending a sponsor’s budget constraints can also aid in establishing equitable objectives and requests during discussions, especially when considering the clinical trial cost in Chile and the financial benefits of performing studies in Latin America.
    • Utilize Cost-Effective Resources: Choose regional suppliers for clinical trial materials and services to minimize shipping costs and import taxes. Not only does this lower expenses, but it also supports the regional economy, creating a more sustainable operational model. Furthermore, using regional resources can improve compliance with regulatory authorities such as the Instituto de Salud Pública (ISP) and ensure adherence to ICH-GCP standards. Bioaccess® can assist in navigating these local resources effectively.

    By implementing these strategies, startups can effectively manage their finances. It keeps studies within budget while navigating the regulatory landscape set by authorities like the ISP and adhering to ICH-GCP standards. Avoiding common pitfalls in budgeting can be the difference between a successful trial and financial strain.

    The central node represents the overall theme of budgeting and cost management. Each branch shows a key technique, and the sub-branches provide specific actions or insights related to that technique. This layout helps you see how each strategy connects to the overall goal of effective financial management in clinical trials.

    Navigating Chile’s regulatory landscape can be a daunting task for startups aiming to conduct clinical research. Chile’s regulatory framework for research studies is overseen by the Instituto de Salud Pública (ISP), which enforces adherence to ICH-GCP standards. Startups can significantly reduce trial costs by implementing these strategic approaches:

    • Understand Approval Timelines: The average approval time for clinical trials in Chile is approximately 30 business days. Planning submissions with this timeline in mind can help mitigate potential delays. Delays in approval can lead to increased timelines and a higher clinical trial cost in Chile for startups.
    • Prepare Comprehensive Documentation: Ensure that all necessary documents, including the clinical research protocol, informed consent forms, and investigator brochures, are meticulously prepared to meet ISP requirements. This thorough preparation is critical for successful approval.
    • Engage Local Regulatory Experts: Collaborating with local regulatory consultants, such as bioaccess®, can facilitate smoother interactions with the ISP and help navigate bureaucratic hurdles effectively. Without local expertise, startups risk facing bureaucratic challenges that could hinder their progress. Bioaccess® has successfully assisted numerous clients in achieving timely approvals, leveraging its extensive experience in the region.
    • Utilize Fast-Track Pathways: Leverage Chile’s fast-track approval processes for innovative therapies, which can significantly reduce time to market and enhance the overall efficiency of study execution. For example, bioaccess® has assisted clients in accelerating their studies through these pathways, demonstrating the potential for quicker patient enrollment and lower clinical trial cost in Chile.

    With bioaccess® guiding them through regulatory obligations, startups can minimize delays and costs, paving the way for a faster market entry.

    This flowchart outlines the steps startups can take to navigate Chile's regulatory landscape for clinical trials. Each box represents a strategic approach, and the arrows show how these steps connect to help reduce costs and streamline the approval process.

    Leverage Local Partnerships for Cost-Effective Trial Execution

    Navigating the complexities of clinical study execution in Chile can be daunting for startups, but strategic regional collaborations offer a powerful solution. Startups should consider:

    • Collaborating with Local CROs: Partnering with local Contract Research Organizations (CROs) like bioaccess® provides access to established networks, significantly reducing the time and cost associated with site selection and patient recruitment. Local CROs are well-versed in the regulatory landscape governed by the Instituto de Salud Pública (ISP), ensuring compliance with ICH-GCP standards and facilitating faster approvals, often within 30 business days.
    • Engaging with Academic Institutions: Collaborating with universities and research institutions allows startups to leverage their resources, including extensive patient databases and research expertise. This collaboration can enhance recruitment efforts and improve study design, ultimately leading to more efficient execution of research.
    • Building Relationships with Investigators: Cultivating strong connections with regional researchers who possess expertise in conducting medical studies is essential. Their insights can improve study protocols and enhance operational execution, ensuring that research is customized to the regional context and regulatory requirements.
    • Utilizing Community Engagement: Interacting with regional communities is crucial for establishing trust and promoting involvement in research studies. Effective community outreach can lead to quicker recruitment and enhanced retention rates, which are vital for the success of research studies.

    Startups often struggle with the complexities of clinical study execution, leading to delays and increased costs. By forming strategic partnerships, they can navigate these challenges more effectively, ensuring timely and cost-efficient study execution. Embracing these collaborative strategies not only streamlines operations but also positions startups to thrive in the evolving MedTech and Biopharma landscape.

    The central idea is about leveraging local partnerships. Each branch represents a different strategy that startups can use to improve their clinical trials. The sub-branches provide more details on how each strategy can help, making it easier to see the connections and benefits.

    Conclusion

    Navigating the complexities of clinical trials can be daunting for startups, especially in a foreign market like Chile, where opportunities abound. Chile offers a unique advantage for clinical trials, particularly for first-in-human studies, due to its significantly lower costs compared to developed markets. Startups can navigate the financial landscape, use smart budgeting techniques, and build local partnerships to streamline their clinical trial processes while staying compliant and efficient. These strategies are essential for achieving successful study outcomes while maintaining financial stability.

    The article outlines several best practices that can enhance cost management in clinical trials. Key strategies include:

    1. Detailed budget forecasting
    2. Regular budget reviews
    3. Negotiating favorable contracts with vendors

    Additionally, understanding the regulatory framework and engaging local experts can expedite approval processes and lower overall costs. Collaborating with local CROs, academic institutions, and community stakeholders further streamlines execution and fosters trust, ultimately enhancing patient recruitment and retention.

    In conclusion, embracing these strategies not only positions startups for success but also redefines the landscape of clinical research in Latin America. By adopting these best practices, MedTech and Biopharma startups can navigate the complexities of early-stage clinical research and accelerate their timeline to market, making Chile an ideal choice for innovative clinical studies.

    Frequently Asked Questions

    Why is Chile considered a prime destination for clinical research, particularly for first-in-human studies?

    Chile is considered a prime destination for clinical research due to significantly lower clinical trial costs, which can be 30% to 75% lower than in the U.S. and Europe. This cost efficiency is attractive for sponsors, especially startups.

    What factors contribute to the lower clinical trial costs in Chile?

    Key factors contributing to lower clinical trial costs in Chile include lower site costs due to reduced overhead, government incentives such as tax breaks and grants, access to regional venture capital and funding programs, and a supportive regulatory framework.

    What types of government incentives are available for clinical research in Chile?

    The Chilean government offers various incentives for clinical research, including tax breaks and grants aimed at innovative studies, which can help reduce the overall costs of conducting clinical trials.

    How can startups access funding for clinical trials in Chile?

    Startups can access funding through regional venture capital and government funding programs specifically designed to support healthcare innovations, which can enhance their financial viability for clinical trials.

    What is the regulatory framework for conducting clinical trials in Chile?

    The regulatory framework in Chile requires compliance with the Instituto de Salud Pública (ISP) and adherence to ICH-GCP standards. Understanding submission pathways and approval timelines is essential for study approval.

    How can sponsors optimize their budgets when conducting clinical trials in Chile?

    Sponsors can optimize their budgets by understanding financial dynamics and regulatory requirements, allowing for effective resource allocation to hit first-in-human milestones without exhausting capital reserves.

    How do per-patient expenditures in Chile compare to those in the U.S. and Europe?

    Per-patient expenditures in Latin America, including Chile, range from $15,000 to $35,000, compared to $40,000 to $75,000 in the U.S. and Europe, highlighting the financial advantages of conducting studies in Chile.

    What role does bioaccess® play in navigating the financial landscape of clinical trials in Chile?

    Insights from bioaccess® help MedTech startups navigate the financial landscapes effectively, ensuring successful study outcomes by optimizing budgets and understanding the regulatory environment.

    List of Sources

    1. Understand the Financial Landscape of Clinical Trials in Chile
      • scielo.cl (https://scielo.cl/article_plus.php?pid=S0034-98872021000100110&tlng=en&lng=es)
      • reedintelligence.com (https://reedintelligence.com/insights/clinical-trial-management-system-market/chile)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOoqs38GZHJgcHiGuq3l1mJ6EOqPFlA_xvgkVOi4V8PVjFF_S2NKn)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trial-supply-logistics-market/chile)
      • Costs & Timelines | bioaccess® (https://bioaccessla.com/costs-and-timelines)
    2. Implement Strategic Budgeting and Cost Management Techniques
      • integrait.co (https://integrait.co/latam-clinical-research-sites-operating-costs-2024)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOoqY-XIdCuCM7cCI0sdrhRlG1DZP2FyMTX8Pi45ix1E8_PTyijgE)
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/clinical-trials-budgeting-and-forecasting-six-simple-steps-to-immediately-improve-accuracy-5018849-2)
      • Strategies For Efficient Clinical Trial Budget Management (https://advarra.com/blog/strategies-for-efficient-clinical-trial-budget-management)
    3. Navigate Regulatory Requirements to Optimize Trial Costs
      • Clinical Trials in Latin America (https://languageconnections.com/clinical-trials-in-latin-america)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • Navigate Biopharma Clinical Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/navigate-biopharma-clinical-trials-in-chile-a-step-by-step-guide)
    4. Leverage Local Partnerships for Cost-Effective Trial Execution
      • bioaccessla.com (https://bioaccessla.com/blog/best-practices-for-clinical-trial-outsourcing-in-chile)
      • What is a Contract Research Organization in Chile? | bioaccess® (https://bioaccessla.com/blog/what-is-a-contract-research-organization-in-chile)
      • linkedin.com (https://linkedin.com/posts/juliomartinezclark_how-chile-is-shaping-medical-device-clinical-activity-7259074399159349248-2aFu)
      • Contract Research Organization Market Forecast, 2026-2033 (https://coherentmarketinsights.com/industry-reports/contract-research-organization-market)
      • aamchealthjustice.org (https://aamchealthjustice.org/news/viewpoint/local-partnerships-key)